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Abstract 
 
Objective:  To test the efficacy and impact of a concentrated green tea extract to improve 
lipid profile in postmenopausal women.  
Methods:  886 postmenopausal women were recruited in to the study and randomized to 
consume either 1200 mg of a green tea catechin extract (“GTE”, 800 mg as EGCG) or 
placebo, daily.  Fasting serum samples were drawn for measure of lipid panel at baseline, 
midpoint (month 6), and endpoint (month 12) of study, to be analyzed. 
Results:  After one year on treatment, total cholesterol (“TC”, -4.6 mg/dL, P<.0001), 
LDL-C (-5.0 mg/dL, P<.0001), and non-HDL cholesterol (-4.4 mg/dL, P>.0001) were 
significantly reduced in the GTE group, both compared to placebo and overall.  The 
largest reductions in TC, LDL-C, and non-HDLC occurred in participants with baseline 
total cholesterol > 200 mg/dL.  HDL-C decreased slightly in the GTE group, both after 6 
months on treatment (P=.0016), and overall (P=.0038).  Triglycerides increased 
significantly after one year in the GTE group compared to placebo (+3.5 mg/dL, P=.023) 
as well.  A similar trend was seen in participants who took statins during the trial, had a 
baseline TC <240 mg/dL, or had a baseline of BMI < 24.9 or > 30 kg/m
2
.
Conclusion:  Daily supplementation of GTE at 1200 mg (800 mg as EGCG) for one year 
resulted in significant reductions in TC, LDL-C, and Non-HDLC in a population of 
postmenopausal women.  Further research in to proper dosing guidelines, in particular for 
hyperlipidemic populations, would be beneficial to increase potential therapeutic use of 
these findings.
  1 
 
 
 
 
 
 
 
 
Chapter One: The Literature Review 
 
 
 
 
 
 
 
 
 
 
  2 
1.   Green Tea and Catechins 
 Green tea comes from the plant Camellia Sinensis. It is one of the most popular 
and widely-consumed beverages in the world, and has been a source hydration, medicine, 
and tradition for centuries.  The antioxidant
1
, antiatherosclerotic
2
, 
antihypercholesterolemic
3
, and anticarcinogenic
4
 properties of green tea demonstrated 
through in vivo, in vitro and animal studies, have fueled further interest and research in 
this field.  A growing body of evidence suggests the many beneficial applications of 
green tea (sections 3-7, in this review), and active research in to the extent of these 
benefits in ongoing.  However, in order to understand the potential of this plant and 
compounds, it is important to understand its composition, origin, and preparation.            
 Green tea is the least fermented tea of the Camellia Sinensis varieties (green, 
black, and oolong teas).  Because of this, the high polyphenolic content of the virgin plant 
is preserved.  The catechins, a type of polyphenol, are the biologically active compounds 
believed to be responsible for the health-promoting properties of green tea
5
.  Chung S. 
Yang et al. report there are around 620-880 mg of water-extractable solids in an average 
tea bag-sized tea and water infusion (~two grams tea leaves in eight ounces water).  The 
catechins account for about 30% of the dry weight of the tea leaves, with epigallocatechin 
gallate (EGCG) comprising on average 45-80% of that weight
1,6
.  Three of the other 
primary catechins present in green tea include epicatechin (EC), epicatechin gallate 
(ECG), and epigallocatechin (EGC): 
  3 
               
 
          
 
Figure 1.  Chemical structures of the major catechins in green tea. 
 
 
Green tea catechins are primarily absorbed in the small intestine, and metabolized by 
Phase II enzymes including sulphotransferases (SULTs), UDP-glucuronosyltransferases 
(UGTs), and catechol-O-methyltransferase (COMT), with further metabolism occurring 
in the liver.  EC and EGC appear to be preferentially metabolized in enterocytes during 
absorption, since their conjugated forms are found more in plasma, versus EGCG and 
ECG being found in their free form
7
.   
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 The overall bioavailability of the catechins in humans has been questioned 
however, since catechins (especially EGCG) are rapidly degraded in the intestine upon 
being consumed
7
.  Large catechins that cannot be absorbed in the small intestine often 
pass on to the large intestine, where they can be broken down into smaller metabolites by 
microbiota in the colon
8
.  A paper by Calani et al. investigated the contribution of these 
colon-derived metabolites to overall catechin bioavailability, finding they greatly 
increased bioavailability of catechins absorbed by the human body when compared to 
intestinal absorption alone.  This contribution of colon-derived catechin metabolites may 
account for some of the inter-individual variability of absorption seen in tea consumers
8
.   
 Green tea catechins are relatively stable compounds.  They are most stable in 
acidic conditions (pH <4), and degrade quickly in alkaline solutions.  Relative to brewing 
in water alone (average pH ~7), there is a 20% increase in EGCG content at pH 3, which 
is comparable to a cup of tea with 10 mL of lemon juice added during steeping
9
.  One 
theory for the low bioavailability of orally ingested catechins is the change (increase) in 
pH from the stomach to the intestine, with EGCG and EGC being more readily degraded 
in alkaline solution than EC and ECG
7
.  Aside from being pH-dependent, catechins are 
quite heat-stable.  The concentration of EGCG and related catechins in a tea infusion is 
highest after ~7 minutes of steeping in 100 degree Celsius water
9
, and exhibit only ~15% 
reduction in catechin concentration after being boiled in water for up to 7 hours
10
. 
 Tea is a natural plant native to certain parts of the world, most notably China and 
Japan.  Like tea flavor, from mild and mellow, to fruity, bold or grassy, there are various 
factors that affect tea catechin content.  Season of harvest, leaf age, and sun exposure 
  5 
during growth are all associated factors
11
.  A study by Song et al. found a slight inverse 
association between EGCG content and sun exposure, with content increasing from bud 
to first leaf (P=.01), as long as the plant was also partially shaded (receiving 60% shade, 
P<.001).  Without partial shade cover, this association was not observed.  Interestingly, 
inter-catechin variations may also exist, given the same growing conditions.  In the same 
study for example, EGC was strongly correlated with leaf age (increasing with leaf age, 
P<.0001), with less dependence on shade level (P<.05)
11
.  It is logical to consider the 
temperature and photosynthetic differences in shaded vs. exposed plants, however the 
direct effect of shade versus other environmental factors on catechin content in teas is 
still unclear
11
.  Aside from environmental factors, catechin content in commercial teas 
may be influenced by steeping temperature and length, manufacturing process (highest 
with air-tight packaging), cultivar and origin (immense variety), and pH of infusion.  
Differences in catechin content have even been shown between lots of the same type and 
brand of tea, highlighting some susceptibility to variation at many points during the 
growth and production chain
12
. 
  
2.   Lipids and Lipid Metabolism 
2.1   Digestion and Absorption  
In order to understand how catechins from green tea may affect lipid profile, a 
brief overview of lipid and lipoprotein metabolism is provided.  Triglycerides are the 
most common lipid found in the diet.  A triglyceride molecule consists of a glycerol 
backbone esterified to three fatty acids (FAs), which can vary in length (short, medium, 
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or long-chain), as well as degree of saturation (saturated, monounsaturated, and 
polyunsaturated)
13
.  Digestion of lipids begins in the stomach by gastric lipase, but occurs 
primarily in the small intestine where lipids are absorbed
14
.  Partially-digested lipids from 
the stomach assemble in to small droplets and enter the duodenum of the small intestine, 
stimulating the gall bladder to express bile into the lumen.  Bile functions to make the 
hydrophobic lipid droplets soluble in the aqueous lumen, a feat made possible by its 
amphipathic components, including bile salts and phospholipids
14
.  The churning of the 
bile and lipid droplets in the duodenum result in the production of tiny aggregates called 
mixed micelles, composed of partially hydrolyzed triglycerides, phospholipids, bile salts, 
cholesterol, and fat-soluble vitamins.  Pancreatic lipase and colipase act upon these 
micelles, hydrolyzing any remaining full triglycerides in to free fatty acids and 
monoglycerides, which enter the enterocyte via simple diffusion or fatty acid transport 
proteins
15,16
.  Cholesterol can only be absorbed in the free form, so dietary cholesterol 
esters must be hydrolyzed by pancreatic cholesterol esterase prior to absorption
17
. 
It is known that about 50% of cholesterol consumed in the diet is actually 
absorbed
18
, however clarifying the exact metabolic pathway is still an active area of 
research.  In 2004, Altmann and Davis, et al., reported their identification of a 
transmembrane protein vital for intestinal absorption of cholesterol, the Niemann-Pick C1 
like 1 (NPC1L1) protein
19
.  Prior to the discovery of NPC1L1, the mechanism by which 
cholesterol entered the enterocyte from micelles was poorly understood.  The generally 
accepted mechanism was free cholesterol could enter intestinal cells via passive 
diffusion, but the presence of NPC1L1 challenges this theory.  Further research has 
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supported a central role for NPC1L1 protein in cholesterol homeostasis as well.  Harry R. 
Davis Jr. and colleagues used NPC1L1 knockout mice to demonstrate its influence on in 
vivo cholesterol regulation.  In NPC1L1 (-/-) mice, intestinal absorption of cholesterol 
was inhibited.  A compensatory increase in intestinal and liver expression of cholesterol 
biosynthetic enzymes and an upregulation of low-density lipoprotein (LDL)-receptor 
proteins was also observed.  The result was increased LDL cholesterol (LDL-C) 
clearance from the plasma and increased biosynthesis of cholesterol.  In wild type mice, 
cholesterol balance is in part controlled by monitoring cholesterol absorption from the 
intestine.  In the current study, cholesterol feeding in healthy wild-type mice caused a 
down-regulation of NPC1L1 protein transcription, which is believed to act as a primary 
barrier against over-absorption of cholesterol
20
.   
As with cholesterol, the prevailing theory for triglyceride absorption was passive 
diffusion of hydrolyzed monoglycerides and free fatty acids via the apical membrane of 
enterocytes.   Though this method is feasible for short and medium-chain fatty acids, 
growing support for the use of facilitated diffusion is strong, particularly for long chain 
fatty acids (LCFAs).  Min Chen et al., explored this theory in rat enterocytes, and found 
substantial evidence to suggest a key role of the multifunctional enzyme CD36 (Fatty 
Acid Translocase in rat enterocyte) in LCFA intestinal absorption
15
.  Once in the 
enterocyte, the free fatty acid or monoglyceride molecule is bound by an intracellular 
fatty acid binding protein (FABP), which chaperones the lipid to its active site of 
function
21
.  Most FAs will be reassembled in to a triglyceride, to follow one of four main 
pathways: incorporation in to chylomicrons, storage within the cell, incorporation in to 
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fatty acid products (ie: cholesterol esters), or used for energy via beta oxidation.  A 
significant number of dietary triglycerides will be packaged in to chylomicrons with fat-
soluble vitamins, cholesterol esters and phospholipids, and released in the lymph to 
eventually enter portal circulation via the thoracic duct and distribute their contents to 
peripheral tissues
22
.  
 
2.2   Cholesterol Biosynthesis 
Humans are able to synthesize enough cholesterol to meet physiological needs.   
Cholesterol is an essential building block of cell membranes, and functions as a precursor 
for steroid hormone synthesis and other compounds important for cell function.  Due to 
its key role in membrane and hormone synthesis, cholesterol balance is a highly regulated 
and monitored process.  If a cell needs cholesterol and dietary cholesterol is not 
sufficient, the cell will upregulate transcription of cholesterol-synthesizing enzymes, in 
particular 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
23
.  In 
summary, cholesterol begins its synthesis by merging molecules of acetyl-CoA to form 
acetoacetate.  Acetoacetate is converted in to HMG-CoA through the action of HMG-
CoA synthase, then in to the cholesterol precursor mevalonate by HMG-CoA reductase.  
Mevalonate then undergoes a series of reactions that result in formation of an isoprene 
which continues on to be become cholesterol, or can branch in to synthesis of other 
nonsterol products, such as ubiquinone
24,25
 (Figure 2).  The action of HMG-CoA 
reductase to form mevalonate is the rate-limiting step of cholesterol biosynthesis, and its 
function is regulated by the presence and active status of sterol regulatory element 
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binding protein-2 (SREBP2), a transcription factor central to the regulation of many 
metabolic pathways
23
.   When intracellular cholesterol is low, SREBP2 translocates to the 
nucleus and increases transcription of HMG-CoA reductase mRNA, which is translated 
in to the active enzyme as needed.  When intracellular cholesterol is high, SREBP2 is 
deactivated and any SREBP2 in the nucleus is degraded
25
.  Cholesterol not immediately 
needed for synthesis of new cell membranes enters one of four main pathways: 
esterification and storage within the cell (forming a cholesterol pool to be used later), 
conversion in to bile salts, synthesis of steroid hormones, or is added to bile for fecal 
excretion.   The average person synthesizes about 700-900 mg of cholesterol per day, 
with the liver and ilium being the primary organs of synthesis
24
.        
Diet and genetics appear to interact in determining how a person metabolizes 
cholesterol
18
.  With only half of the cholesterol consumed in food being actively 
absorbed
18,19
, much of the cholesterol in our body is of endogenous origin.  Enterohepatic 
circulation is the process of cholesterol being incorporated in to bile to aid digestion, then 
its re-absorption in the distal intestine (ileum) and recycling in the liver, to be used again 
in bile, excreted, or for the synthesis of other compounds.  Composed of bile acids 
(derived from cholesterol), phospholipids, and free cholesterol, bile is a primary route for 
excretion of excess cholesterol in humans, responsible for up to 500 mg of excreted 
cholesterol per day
26
.   
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Figure 2.  Cholesterol biosynthetic pathway (overview)
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2.3   Lipoproteins and Apolipoproteins 
The method of classifying lipoproteins by density, based on the composition of  
their lipid core, has helped to define the distinct roles of these compounds.  Lipoproteins 
are protein-lipid complexes made water-soluble by the presence of a phospholipid-
enriched membrane, with the primary function of transporting and distributing lipids 
throughout the body.  The apolipoproteins are type-specific functional accessory proteins 
located on and around the surface membrane, and are largely responsible for determining 
the physiological activities of each lipoprotein.     
Two primary classes of apolipoproteins define the lipoprotein density categories: 
apolipoprotein A-containing (apoA), and apolipoprotein B-containing (apoB).  The 
apoA-containing lipoproteins have the highest proportion of phospholipids, and are 
generally associated with high density lipoprotein cholesterol (HDL-C).  The apoB-
containing lipoproteins have a higher percentage of cholesterol esters and triglycerides in 
their lipid core, reducing the density of their core to the level of low-density (LDL-C) or 
very low-density (VLDL-C) lipoproteins
28
.  The apolipoproteins act as ligands for 
binding to necessary receptors, such as LDL-receptor and scavenger receptor B1 (SR-
B1), and serve as identifiers on the lipoprotein surface.  The apolipoprotein composition 
of the lipoproteins shifts as their contents do.  During the lipid distribution process, the 
ratio of triglyceride to cholesterol ester shifts, converting the VLDL-C first to IDL-C, 
then to LDL-C.  As it releases triglycerides to peripheral tissues, VLDL-C loses its E and 
C apolipoproteins (two apoproteins which appear in various forms on many lipoproteins), 
making B-100 the primary apolipoprotein of LDL-C 
29
. 
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3.   Green Tea and Health 
3.1   Cardiovascular Disease 
Having elevated serum levels of triglycerides, total cholesterol (TC), and LDL-C 
are associated with an increased risk for developing cardiovascular diseases (CVD).  This 
risk is further compounded by having low levels of serum HDL-C, a central component 
of reverse cholesterol transport and cholesterol recycling.  Though there is some 
inconsistency in results regarding green tea and improvement of CVD risk factors, there 
is growing evidence to support an association 
30,31
, via various pathways including 
elevation of HDL-C, increased antioxidant activity, and reduction of blood pressure
32
.  
Suliburska et al. reported a positive change in HDL levels in obese patients receiving a 
moderate dose of green tea catechins (379 mg green tea extract, “GTE”) daily for three 
months.  Though no difference was seen between treatment groups, patients within the 
GTE group experienced significant increases in HDL-C (P<0.044)
33
.  A 2012 
randomized, placebo-controlled double-blind study conducted by Bogdanski and 
colleagues investigated the antiatherogenic potential of green tea catechins as well.  
Three months of daily supplementation (379 mg, 208 mg as EGCG) of green tea extract 
to 56 obese, hypertensive patients significantly reduced blood pressure (SBP: P=0.004, 
DBP: P<0.001), fasting glucose (P=0.016), insulin (P<0.001), and inflammatory factors 
(P<0.001), and increased antioxidant status.  Additionally, a 15% increase in HDL-C was 
observed in the green tea group (P<0.001), as well as significant reductions in TC 
(P=0.009), LDL-C (P=0.011), and triglycerides (P=0.004)
32
.  The large increase in HDL-
C observed in this treatment group is interesting due to great inconsistencies reported in 
  13 
previous green tea lipid trials looking at HDL-C.  All participants were asked to retain 
their diet (monitored by questionnaire every 14 days, plus 3 days before lab visits) and 
physical activity habits in an attempt to isolate the influence of the intervention alone, but 
it is possible differences in fat quality of diet, age, and varying compliance may have 
yielded unintended influence on results
32
. 
The initiation of fatty streak development is atherosclerosis is dependent on the 
action of inflammatory cytokines.   In LDL-receptor knockout mice, an animal model for 
human hypercholesterolemia, four weeks of daily 50 mg/kg supplementation of green tea 
extract (GTE) significantly decreased plasma levels of monocyte chemotactic protein-1 
(MCP-1), an inflammatory cytokine, in atherosclerotic mice.  GTE at 50 mg/kg per day 
also promoted relaxation of the aorta, reduced plasma triglyceride levels, and reduced 
atherosclerotic lesion size (P<0.001) as compared to control hypercholesterolemic 
mice
34
.  Kumaran et al. demonstrated a high cholesterol diet induces more fatty changes 
in hepatic tissue in aged rats, as opposed to young rats.  Daily administration of 100 
mg/kg GTE for 30 days significantly reversed these changes, including hepatic 
cholesterol, triglycerides, serum cholesterol, LDL-C, and VLDL-C
35
.  An in vitro study 
by these same researchers also showed improved resistance to lipid peroxidation, a 
known proliferator of atherosclerosis and cardiovascular disease, in tissues treated with 
EGCG
35
.  Furthermore, Friedrich et al. found in mice fed a high-fat diet supplemented 
with EGCG, post-prandial plasma triglycerides were reduced dose dependently, as well 
as liver triglycerides in the post-prandial state
36
. 
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3.2   Obesity and Type II Diabetes 
Regular green tea consumption has been loosely associated with improving 
symptoms of obesity, type 2 diabetes, and metabolic syndrome, conditions exacerbated 
by the high-calorie diets and sedentary lifestyles of present day.  The metabolic syndrome 
is a cluster of adverse anthropometric and biochemical symptoms, including 
dyslipidemia, hypertension, and elevated fasting glucose (>100 mg/dL)
37
.   Aside from 
being associated with development of type 2 diabetes, obesity can also induce chronic 
inflammation in the body.  Adipose tissue functions not only as lipid storage, but also as 
an endocrine organ, secreting hormones related to appetite, metabolism, and 
inflammation (cytokines).  Adipose tissue accumulation has been linked to a constant 
state of inflammation, leading to many of the complications associated with this 
disease
33
.  
Though this syndrome can affect people of all ages, the loss of the protective 
effects of estrogen in menopause can be conducive to developing this condition in 
postmenopausal women.  Suggested lifestyle interventions for these symptoms include 
emphasis of a plant-based diet (for phytoestrogens and catechins), increased physical 
activity, and weight loss
37
.  Obesity is a growing problem in the United States, making 
research in to its treatment and prevention of great interest.  The anti-obesigenic potential 
of green tea appears to be multi-dimensional, including interaction with catecholamine 
metabolism
38
, increased beta oxidation
39
, and suppression of lipogenic enzymes
40
, among 
others. 
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Some catecholamines (epinephrine, norepinephrine) are stimulators of lipolysis in 
the body.  By inhibiting the enzyme responsible for catecholamine breakdown (catechol-
O-methyltransferase), catechins are thought to increase the duration of the 
catecholamines presence in plasma, prolonging their effects
38
.  Some evidence in human 
studies also shows green tea to potentially increase energy expenditure through enhanced 
thermogenesis and fat oxidation.  A metabolic study in 10 healthy men reported daily 
consumption of 270 mg EGCG for 5.5 weeks was found to increased total 24-hour 
energy expenditure as compared to placebo or caffeine-only (150 mg/day) treatment, by 
3.5% and 2.8% respectively
39
.  These same interactions with tea may not be seen in 
children however.  A 2008 study in Japanese school children by Matsuyama et al. 
investigated the effect of a catechin-enriched (576 mg, 102 mg as EGCG) green tea 
beverage on fat mass, cholesterol, and blood pressure.  Study participants were 
randomized in to treatment groups, then provided either a 340 ml can of catechin-rich  
test beverage (base beverage of tea leaf-water infusion, with catechin extract added), or a 
can of control beverage, to consume once per day for 24 weeks.  The control beverage in 
this study also contained catechin extract (75 mg) to help blind the beverages so they 
would not be discernable by appearance or taste.  Interim and post-treatment analyses 
showed no significant changes in major endpoints (blood pressure, fat mass, BMI) other 
than LDL:HDL ratio
41
.   A randomized, double-blind, placebo-controlled clinical trial in 
78 obese women showed significant reductions in LDL-C (P<0.001) and a slight increase 
in HDL-C (P=0.01-0.05) after 12 weeks of daily 1200 mg GTE supplementation.  These 
changes were only significant for within-group comparison however, and did not 
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maintain that significance in cross-group comparisons
42
.  A significant reduction in 
weight and total percent body fat was found in mice fed a high-fat diet, who consumed 
3.2 g/kg supplemental EGCG every day for 16 weeks.  In the green tea extract-treated 
group, weight gain was 33-41% lower than in the untreated mice consuming a high fat 
diet.  The amount the rats were consuming would equate to about 10 small cups of green 
tea per day
43
.   
Favorable results in green tea and lipid research have led to the development of 
more specific trials to explore its effects in patients with type 2 diabetes as well.   A 
number of animal and in vitro studies provide evidence toward the ability of green tea 
catechins to help ameliorate complications with diabetes, and impact insulin sensitivity.  
Bose et al. reported mice fed a high-fat diet supplemented daily with 3.2 g/kg EGCG for 
16 weeks had 25% lower blood glucose, a 61% reduction in plasma insulin, and a lower 
homeostasis model assessment of insulin resistance score (HOMAIR: a calculation used to 
estimate insulin resistance), than untreated mice fed the same high fat diet
43
.  Waltner-
Law et al. demonstrated in vitro the ability of EGCG to decrease hepatic glucose 
production, via downregulation of the gluconeogenic enzymes phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase
44
.    
Despite promising results in animal studies, human trials have failed to follow suit 
in consistency.  An epidemiological study in Japan reported that those who habitually 
drank six or more cups of green tea per day decreased their risk of developing type II 
diabetes, when compared to those who consumed less than one cup per week
45
.  Han et 
al. reported one potential mechanism to explain this observation.  The in vitro study 
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reported EGCG exerted a protective effect over pancreatic beta cell death, in part by 
reducing the expression of nuclear factor kappa-B (NFkB), a potent transcription-factor 
for many pro-inflammatory molecules
46
.  A study by Nagao at al. reported a significant 
increase in insulin and adiponectin in type II diabetic patients, after 12 weeks of daily 
582.8 mg GTE consumption, though these changes were significant for within treatment 
group only
47
.  In contrast, a study by Brown et al. explored the potential of isolated 
EGCG to improve insulin resistance in 46 overweight or obese non-diabetic males.  
Participants consumed 400 mg of EGCG twice daily for 8 weeks, with no resulting 
impact on insulin resistance as measured by HOMAIR
48
.  Though the proposed 
hypoglycemic effects of green tea are more persuasive in animal trials, the dose of 
catechins given to animals tends to be higher than what would be given to humans, 
complicating dosing guidelines for future human studies.   
 
3.3   Antioxidant Function, Cancer 
A large cohort study published in 2004 (n = 29,199) suggests breast cancer risk in  
postmenopausal women may be increased in those who are overweight or have a history 
of metabolic syndrome, and a slight inverse association of this trend was associated with 
HDL-C quartile
49
.  Though reports on the interaction of catechins and HDL-C 
metabolism have been conflicting, there is a lack of large-scale, placebo-controlled 
studies investigating this relationship. Greater mechanistic support for the anti-
carcinogenic properties of green tea and tea catechins often come from studies conducted 
in animals
50
.  An example of this is a 2013 study by Gu and colleagues which found 
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EGCG (50-100 mg/kg/day) to be protective against induced breast cancer development in 
16 female mice, by inhibiting the activation of NFkB and vascular endothelial growth 
factor (VEGF) in breast tumors.  A cross-section of mouse tumors after two weeks of 
supplementation showed tumor area to be 65% less in the EGCG group (P<0.01), as 
compared to controls
4
.    A number of systemic reviews and meta-analyses have been 
conducted using case-control and cohort data to analyze the chemopreventive potential of 
green tea and catechins
51
.  Well-controlled intervention studies may shed greater light on 
any cause-effect relationship between catechin consumption/supplementation and cancer 
risk. 
Oxidative stress has been implicated in tumor progression as well
4
.  Kumaran et 
al. documented increased levels of lipid peroxidation, and decreased levels of 
glutathione, in aged rats as compared to young control rats. Antioxidants can function by 
donating an electron to unstable compounds to help protect against peroxidation and 
radicalization, or by chelating bioactive metals that can produce oxidation products in the 
body (ex: copper, iron).  Although antioxidant ability reduces with age and cell turnover, 
their experiment showed green tea extract helped restore function, or increase levels, of 
these cellular antioxidant enzymes
52
.  Suliburska et al. also reported significant increases 
(P<0.01) in total antioxidant status in obese participants consuming 379 mg green tea 
catechins (208 as EGCG) per day
33
, and though similar findings have been reported 
relative to the antioxidant function of catechins, their potency in vivo may be questioned 
by a weak bioavailability
50
.  
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4.   Epidemiological Studies: Green Tea and Lipids 
Before any clinical investigation, reports on the health benefits associated with 
consumption of green tea came from observational studies.  One of the largest and most 
widely recognized of these is a 2002 study conducted by Tokunaga et al. which looked at 
the effects of daily consumption of brewed green tea in 13,916 healthy Japanese 
workers
53
.  The researchers reported a significant inverse association between green tea 
consumption and serum cholesterol, which appeared to plateau at around 10 cups per day.  
An interesting aspect of this study is that the researchers broke down the cholesterol-
lowering ability to a “per cup” level, reporting approximately a -0.39 mg/dL reduction of 
TC in men (P=.03), and a -0.46 mg/dL reduction in women (P=.03) associated with each 
cup of green tea drunk per day
53
.  Though this claim could be influenced by many factors 
as well great interindividual variability, therefore complicating its direct usability, it 
makes for an interesting inclusion of the authors to suggest a “per cup” benefit.  These 
values remained statistically significant, even after adjusting for age, BMI, and dietary 
factors, which was an important consideration as 86.7% of their study population 
reported being average daily tea drinkers
53
.  Intriguing findings such as the association 
reported by Tokunaga and colleagues, has sparked further scientific exploration in green 
tea’s hypolipidemic potential.  A cross-sectional study conducted by Kono et al. also 
reported an association between green tea intake and serum total cholesterol in 1,306 
Japanese men.  Total cholesterol was found to be approximately 8 mg/dL lower in the 
serum of men who consumed >9 cups of green tea per day, with no reported association 
with HDL-C and triglycerides
54
.  Conversely, a cross-sectional analysis of self-reported 
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green tea consumption in 630 Japanese men and their 370 wives found no association 
between green tea consumption and serum lipid levels
55
.  Though the large population of 
these studies provides strength for observational evidence, randomized, placebo-
controlled intervention trials are often a stronger indicator of any cause-effect 
relationship that might be present. 
 
5.   Clinical Trials: Green Tea Catechin Extract and Lipids 
Centuries of cultural literature and anecdotal evidence attest to the favorable 
impact of green tea on health.  The biomedical inquiry into these effects however, 
including lipid homeostasis, is relatively new.  Existing studies have tried to quantify the 
impact of green tea on lipid metabolism, through use of green tea beverage, extract, or 
purified catechins.  Though differences may exist between methods of catechin 
administration (expanded in section 6), all of these methods have been tested to some 
degree.  Trials have been conducted in various human populations, encompassing a mix 
of ages, race, gender, and groups with co-morbidities (ie: diabetes, obesity, metabolic 
syndrome).  Though there are studies that do not correlate green tea consumption 
(beverage, extract, or purified catechin) with improvement in lipid parameters
48,55,56
, 
there are a number of trials contributing to the literature that suggest otherwise. 
A randomized, double-blind, placebo-controlled intervention published in 2009 
investigated the effects of a 400 mg daily GTE supplementation on lipid biomarkers in 
healthy men and women.  A significant decrease was seen for total (-5.60%, P=0.011) 
and LDL-C (-6.79%, P=0.037) in male participants in the GTE group after 3 weeks on 
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supplementation.  Additionally, sub-analyses in participants (both male and female) 
showed significant decreases in LDL (P=0.019) in those with baseline LDL-C >99 
mg/dL.  No change was reported for HDL-C or triglycerides
57
.  In contrast, a different 3-
week study in healthy men consuming 714 mg catechins per day found no significant 
impact on lipid profile, except for a slight reduction in total:HDL cholesterol ratio
58
.  
Other clinical trials have focused on the impact of green tea supplementation in 
hypercholesterolemic or obese patients, including those with metabolic syndrome.  
Suliburska and colleagues conducted a double-blind, randomized trial in 46 obese men 
and women, to test the effect of 379 mg GTE per day on blood and anthropometric 
biomarkers
33
.  After three months, significant reductions in BMI (P=0.03), total 
cholesterol (TC, -6.9%, P<0.01), LDL-C (-12.21%, P=0.02), and triglycerides (-15.75%, 
P<0.01) were seen.  Though there was a 14% increase in HDL-C in the treatment group 
after intervention, there was an unexplained 5% increase in HDL-C in the placebo group 
as well, despite both groups being instructed to maintain isocaloric diets and their typical 
exercise habits.  The drastic reduction in triglycerides seen post-treatment in the GTE 
group is uncommon, and may have been a secondary factor to the weight loss rather than 
a direct catechin interaction.  Thus the question may remain if similar results would be 
seen in a cohort of healthy-weight individuals
33
.  Similar effects were not seen in obese 
men.  Brown et al. reported no significant change in lipid biomarkers was observed in 
overweight or obese men after 800 mg daily consumption of isolated EGCG for eight 
weeks
48
. 
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 Two studies also included a dietary intervention component.  A 2009 prospective, 
placebo-controlled crossover study by Batista and colleagues found after daily 
consumption of 250 mg GTE for 16 weeks, participants experienced a significant 
reduction in TC (-3.9%, P=0.006), LDL-C (-4.5%, P=0.026), and BMI (-1.7%, 
P=0.002)
59
.  Non-significant reductions in HDL, and non-significant increases in 
triglycerides and apolipoprotein B were also observed.  The concomitant dietary 
intervention alone resulted in a significant decrease in daily calories (about -500 calories 
per day), percent total fat, percent saturated fat, and  cholesterol, as well as an increase in 
protein (P<0.0001 for all).  All of these dietary changes would have an impact on lipid 
profile, so discerning the actual impact of the GTE versus that of the diet is difficult
59
.  
Similarly, a 2005 study by Erba et al. was designed to investigate effects of a catechin 
supplement in amounts that could be consumed by an average tea drinker, while also 
implementing a dietary modification (participants consumed ~4 servings of fruits and 
vegetables per day, along with normal diet)
60
.  24 healthy women participated in the trial, 
12 consuming two GTE beverages per day (250 mg total catechins), and 12 consuming 
control diet alone.  After 6 weeks, no significant change in lipid profile was observed, 
except a slight reduction in LDL-C within the GTE group (P<0.05)
60
.  Though the 
researchers attempted to control for outside dietary catechins by giving participants a list 
of restricted foods, there was no placebo or blinding associated with the treatment.  
Additionally, fruits and vegetables are a valuable source of fiber in the human diet, and 
soluble fiber in particular is known to have a favorable impact on cholesterol metabolism 
and balance in itself
61
.   
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Most green tea and lipid trials have used serum drawn from fasting patients.  In 
contrast, Unno et al. tested the effects of catechins on postprandial lipid metabolism
62
.  In 
a triple-crossover design, nine male subjects were enrolled and asked to consume a test 
"meal" (one slice of bread spread with butter) and a green tea mixed catechin beverage, to 
assess the effects of the catechins on postprandial triglyceride levels.  Blood was taken at 
baseline (fasting), then at hours 1, 2, 3, 4, and 6 post-meal.  Participants were given a 
control (10 mg catechins), moderate (224 mg), or high (674 mg) dose of catechins to 
consume with each test meal, with a 1 week washout period between treatments.  
Postprandial triglycerides peaked 3 hours after the meal, averaging a 62 mg/dL rise.  The 
high dose of catechins (674 mg total, 243 mg as EGCG) significantly reduced triglyceride 
levels after the test meal, peaking at just over 37 mg/dL (P<0.05)
62
.  This study differs 
from other green tea and lipid trials because it measures the immediate effects of catechin 
consumption.  This interesting concept, if replicated and validated in a larger trial, could 
perhaps lead to guidelines for green tea application in control of postprandial 
triglyceridemia, a known and independent risk factor for atherosclerosis
63
.  The small 
sample size however (n = 3 per treatment arm), does not protect against the variability 
expected if this test were to be repeated again using different volunteers or a different 
population, thus highlighting the need to repeat a larger trial of this theory.   
Along with many other metabolic processes, lipid metabolism also shifts with 
increasing age.  This could perhaps increase the impact of a low-cost, easily attainable 
lipid-modifying intervention for this particular group.  A study by Miyazaki et al. 
investigated the potency of a GTE supplement with a simultaneous walking program in 
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older adults, measuring changes in lipid profile and other anthropometrics
64
.  Though TC 
(-6.10%) and LDL-C (-8.66%) were significantly reduced in the GTE group after 
supplementation for 14 weeks (P<0.05), these were only observed as within-group 
changes.  Between group comparisons of GTE versus placebo did not show any 
significance
64
.  A potential reason for this could be the underlying study design, as a 
walking program, would increase exercise in both the treatment and placebo groups if 
compliance was maintained.  Increasing physical activity is a common recommendation 
for people with dyslipidemia, as it can exert beneficial effects on lipid panel (increased 
HDL-C, reduced triglycerides) and other biomarkers of health and disease
64
.   If the 
walking itself improved lipid parameters in the placebo group, this may have contributed 
to the lack of significance seen in the between-group analyses.  Additionally, participants 
were asked to continue their typical diet, with no restrictions on food or beverages 
containing catechins or polyphenols (including green tea), making it difficult to assess the 
actual total dose of catechins consumed per day by the treatment group. 
In a study in adult women without the exercise component, however, similar 
improvements in lipid profile were still seen.  A 2012 randomized, placebo-controlled 
study by Wu et al. supplemented 103 postmenopausal women with either 400 mg or 800 
mg of GTE daily for two months
65
.  Within-group comparisons showed significant 
reductions in TC (-5.0%, P=0.012) and LDL-C (-7.9%, P=0.007) in the 400 mg group, as 
well as in the 800 mg group (TC: -3.1%, P=0.045; LDL-C: -6.6%, P=0.012).  Overall, 
only the reduction in LDL was significant when compared to placebo group (P=0.021), 
though TC was borderline (P=0.072).  No treatment effect was seen in HDL-C or 
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triglyceride levels
65
.  Postmenopausal women represent a population that may especially 
benefit from improvements to lipid profile, due to natural anthropometric and metabolic 
shifts that occur during menopause.  The baseline values of TC and LDL-C in the Wu 
and colleagues study designate these subjects as borderline hypercholesterolemic, which 
previous trials suggest may be associated with a more favorable response to a green tea 
intervention.  A 2009 study by Derby and colleagues compared the impacts of both 
menopausal transition and advancing age on lipid biomarkers in women.  The researchers 
determined this by monitoring lipid changes over the natural (uterus and at least one 
ovary intact) pre- to post-menopausal transition in 2,659 American women.  Baseline 
lipid panels were performed on fasting serum samples, and follow-up occurred at one 
year, then once annually in years 3-7. Both estradiol and follicle-stimulating hormone 
(FSH) were monitored in participants to verify menopausal status.  Total and LDL 
cholesterol increased significantly during the pre- to postmenopausal transition (P<0.001 
for both), peaking during early postmenopause
66
. 
Overall, in studies reporting significant reductions in TC and LDL-C
33,57,59,60,64,65
, 
the average reduction was around 6.3% and 9.54%, respectively.  Though very suggestive 
in their findings, existing studies in green tea and lipid profile vary considerably in 
population, design (length, treatment, control of outside factors), and dose or type of 
treatment administered.  Also, variation in sub-analyses, within- versus between group 
comparison reporting, alternate p-values, and confusing or dissimilar discussions of 
findings, make the overall interpretation of these results difficult.  The tendency to 
conclusively state a significant (or lack thereof) effect of GTE consumption after a short 
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duration trial, or in small sample sizes, might add to the discrepancies seen as well.  Of 
the above-mentioned studies, most end their conclusion with the call for a larger, 
placebo-controlled clinical trial to confirm or contest previously stated findings.  
 
6.   Green Tea Beverage and Lipids 
In discussing the interaction of green tea and lipid metabolism, it is important to  
acknowledge that the type of intervention may impact the results observed.  A traditional 
hot water infusion of the green tea leaf contains numerous compounds including proteins, 
amino acids, carbohydrates, vitamins, minerals, chlorophyll and flavonoids 
(polyphenols/catechins)
67
, that are lost when the catechins are separated from the whole 
tea leaf.  The potential for a synergistic (or antagonistic) effect is quite possible between 
these other constituents and the catechins in vivo, though generally trials relating green 
tea to lipids using beverage and GTE have produced similar results
68
.  Additionally, the 
overall health-promoting properties of green tea are supported by a wide spectrum of 
studies, especially observational studies, which helps demonstrate the effects of whole 
leaf brewing versus catechin supplementation alone. 
Many studies, particularly clinical trials intent on determining a cause-effect 
relationship, use a catechin extract intervention.  This is advantageous for a few reasons.  
Catechin dose can be better monitored and controlled when delivered as a pre-determined 
amount in encapsulated form.  The added convenience of ingesting a few capsules, as 
opposed to being asked to brew 1-10 cups of tea per day, likely increases compliance to a 
protocol as well.  An example of this comes from a study conducted in 2010 by Arpita 
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Basu and collegues.  In this randomized, controlled trial, the researchers compared the 
effects of green tea consumption on biomarkers of health in obese men and women with 
metabolic syndrome.  The treatments were brewed green tea (928 mg catechins, 440 as 
EGCG; tea bags from a commercially available brand), a green tea catechin extract 
("GTE": 870 mg catechins, 460 as EGCG), or control (4 cups water), consumed daily for 
8 weeks.  The researchers recognized the potential for inconsistencies in asking 
participants to brew and consume 4 cups green tea per day on their own.  To circumvent 
this, subjects in the green tea beverage group were asked to come to the testing center 
each day to receive their morning dose of tea (2 cups), and were given a canister filled 
with 2 cups of tea to consume later with dinner.  The control and GTE groups only 
returned to the center every few weeks for compliance measurements and/or to receive 
more supplement (GTE group)
69
.   
Interestingly, in contrast to many of the clinical trials looking at GTE and lipid 
parameters, no significant association was found between the extract group and changes 
in lipid profile.  In the beverage group, a trend toward significant decreases in LDL-C 
and LDL/HDL ratio were observed (P<0.1).  Also unlike most of the extract trials, 
participants in the green tea beverage group showed trends toward increasing levels of 
HDL-C (P=0.08)
69
.  A notable component of this study was the researcher’s decision to 
also measure changes in lipoprotein size and composition.  Though a reduction of small 
LDL-C (atherogenic) particles was seen in the GTE group when compared to age and 
gender-matched controls, this change did not reach statistical significance.  The 
researchers reported green tea beverage improved biomarkers of oxidative stress, which 
  28 
was not seen in the catechin extract group.  Whether this disparity is due to different 
sample size or bioavailability of the catechins (in beverage versus extract) is not known, 
but it does present a question of their differing biokinetics
69
.  Consuming 800 mg of 
catechins per day, via extract or capsule form, is comparable to consuming 8-10 cups of 
moderate-strength brewed green tea per day
48
. 
A randomized, placebo-controlled study by Bertipaglia et al. also administered a 
brewed green tea beverage (3 grams of green tea leaves in 500 mL water; ~145 mg 
EGCG per day) daily to hypercholesterolemic patients and monitored changes in lipid 
profile.  After 90 days, non-significant increases in TC, LDL-C, HDL-C and triglycerides 
were seen in the green tea group compared to controls
70
.  The unexpected upward shift of 
lipid parameters post-intervention, though not statistically significant, is of interest 
because the amount consumed in the study is a volume widely achievable by the general 
public, equal to ~2 cups of green tea per day.  One potential explanation of this is the 
control group was actually prescribed a diet low in saturated fats and cholesterol (and 
high in polyunsaturated fats), which the green tea group was not.   Therefore, lipid profile 
could have improved in the control group, making even a lack of change from baseline in 
the green tea group appear to be adverse.   
 
7.   Green Tea and Cholesterol Lowering Mechanisms 
7.1   Suppression of Biosynthesis 
Recognizing the pathways by which green tea may interfere with lipid regulation 
is a matter of active research.  Researchers have employed various methods to test the 
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hypothesis that catechins may inhibit or suppress enzymes in lipogenic pathways
71–74
.  
Though exact mechanisms underlying these interactions are not fully understood, most of 
what is known has been contributed by animal and in vitro experiments.   
Green tea extract (GTE) administered daily to obese mice was found to suppress 
hepatic malic enzyme activity by 67.3% (P<0.001), as well as significantly reduce acyl 
CoA: cholesterol acyltransferase activity (P<0.01), indicating hypolipidemic effects on 
fatty acid synthesis (by reducing substrate) and cholesterol regulation in green tea treated 
groups.  There was no change in HMG-CoA reductase activity between groups
71
.  
Contrary to this, Cuccioloni et al. showed green tea to be a potent inhibitor of HMG-CoA 
reductase in vitro through competitive binding of the active site on the enzyme, as well as 
a potential for it to act synergistically with statin drugs to increase efficacy of treatment
72
.   
Additionally, increased presence and activity of cellular LDL receptor has been 
suggested.  A study by Bursill et al. reported a dose-dependent increase in LDL receptor 
activity in vivo, using a rat model.  In rats supplemented with 2% GTE in rat chow daily, 
LDL receptor protein transcription was found to be significantly higher (P<0.05) than in 
control animals, indicating increased uptake of LDL from plasma in treated rats, exerting 
a hypocholesterolemic effect
75
.   
Inhibition of biosynthesis does not only refer to the enzymes involved in lipid 
synthesis, it may pertain to its carriers as well.  Apolipoprotein B-100 (apoB) is one of 
the main structural proteins on VLDL-C and LDL-C molecules, and it can be used as a 
biomarker of coronary artery disease risk
73
.  In an in vitro experiment by Yee et al., the 
effects of EGCG on inhibition of apoB secretion in a human hepatoma cell line, HepG2, 
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was tested.  25-hydroxycholesterol was added to test medium to simulate a lipid-rich 
environment, causing a two-fold stimulation in apoB secretion as compared to control 
cells.  The addition of EGCG to this test medium reduced the effect of the 25-
hydroxycholesterol by about 95%, indicating a protective effect of the catechins against 
cholesterol-stimulated apoB (VLDL-C, LDL-C) secretion in the in vitro setting
73
.  
Though the direct extrapolation of findings from in vitro and animal studies to clinical 
human use is complicated, they do provide a basis for the mechanistic understanding of 
how catechins may interact with lipid metabolism in favor of improved homeostasis. 
 
7.2   Interference with Lipid Absorption 
Several in vitro studies have provided data pointing toward the possible 
mechanism of green tea inhibition of lipid absorption.  A 2006 study by Shishikura et al. 
tested the emulsification properties of a lipid mixture (olive oil, phosphatidylcholine, and 
bile salts) exposed to various green tea catechins.  The amount of catechins used in this 
experiment were considered achievable by typical daily consumption.  Lipid droplet size 
increased with the addition of the catechins, thus decreasing the surface area exposed to 
the hydrolyzing effects of the lipases
76
.  Lipolysis of core triglycerides in emulsion 
droplets is essential for their absorption, since they cannot be absorbed as whole 
triglycerides.  A distinguishing characteristic of EGCG is the presence of multiple 
hydroxyl groups on its ring structure.  In the Shishikura study, EGCG was one of the 
main components found on the lipid-water interface of the emulsion droplet, 
demonstrating its role as an inhibitor of intestinal lipolysis.  The investigators 
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hypothesized these hydroxyl groups allow for EGCG-mediated hydrogen bonding 
between neighboring emulsion droplets, causing coalescence and an increase in droplet 
size
76
.  A 2003 study by Raederstorff et al. also found EGCG to modify micelle 
formation and solubilization, contributing to reduced intestinal absorption of cholesterol.  
In rats given a lipid emulsion test meal supplemented with 0.1-0.5 g/kg EGCG, intestinal 
cholesterol absorption was reduced by ~7% - 21%, compared to controls
77
.   
Wang, Noh, and Koo demonstrated in vitro the ability of green tea catechins to 
inhibit pancreatic phospholipase A2 (PLA2), an enzyme necessary for the hydrolysis of 
phospholipids on the surface of emulsion droplets.  Without the action of PLA2 on lipid 
droplets, the lipid core cannot be hydrolyzed, preventing formation of mixed micelles and 
hindering the uptake of the lipids.  EGCG exerted the greatest inhibitory effect on 
PLA2
78
.  Further compounding these effects, a study with intestinal cells suggested a 
minimum amount of triglyceride must first be hydrolyzed from micelles in order to 
stimulate cellular uptake of other hydrophobic compounds, such as cholesterol and fat-
soluble vitamins
79
.  Animal studies showing an increase in fecal lipid excretion in mice 
given an EGCG extract also support this theory
43
.  This may explain interesting findings 
of another study by Bursill et al., who propose a potentially greater cholesterol-lowering 
ability of tea catechins occurs when consumed in the same medium as the cholesterol (ie: 
diet)
80
.  The physiologic barriers complicating the absorption of green tea catechins in the 
intestine further support the likelihood of decreased intestinal absorption being a primary 
mechanism for their lipid-lowering effects
7
.   
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8.   Conclusion 
Interest in the health-promoting properties of green tea has continued to fuel 
literature published in this area.  Existing clinical trials investigating the effects of green 
tea catechins on lipid profile have provided intriguing evidence for the hypolipidemic 
properties of these compounds in humans, particularly in the ability of green tea and GTE 
to significantly reduce LDL-C.  As shown in section 5 however, these trials have been 
relatively small (n = 9 to 111), short in duration (3 to 24 weeks), and produced mixed or 
contradictory results relative to other studies.  A few also co-administered green tea 
treatment with a diet intervention, making it hard to distinguish the impact of the diet 
versus that of the catechins on lipid profile.  Many of these reports also include in their 
conclusion a call for larger, randomized, placebo-controlled intervention trials to support 
the suggestive results of smaller trials, in order to better define any cause-effect 
relationship present.  Postmenopausal women in particular are a population at increased 
risk of various conditions including CVD, and to our knowledge, only one other small 
and short-duration study
65
 has investigated the effects of green tea on lipid profile in this 
population.  Three recent meta-analyses summarizing trials of green tea and serum lipids 
have also been conducted
3,68,81
.  Though both meta-analyses from 2011 reported 
significant overall reductions in TC and LDL-C with green tea consumption, one reported 
no statistically significant heterogeneity between studies
68
, and the other did report 
significant heterogeneity between studies which impacted results
3
.  This is despite about 
half the studies in each review being the same as those analyzed in the other review.  
Overall, the results of epidemiological studies and randomized clinical trials showing 
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beneficial effects of green tea on lipid and disease biomarkers is promising, and warrant 
further study in this potentially high-impact area. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  34 
 
 
 
 
 
 
Chapter Two:  
Effects of Green Tea Catechin Extract on Serum Lipids in 
Postmenopausal Women: A Randomized, Placebo-Controlled  
Clinical Trial 
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1.   Background 
Green tea and epigallocatechin gallate (EGCG) have been shown in various 
human and animal trials to exert hypocholesterolemic effects in vivo, particularly on total 
cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C).  Recent meta-analyses 
of green tea and lipid clinical trials (2-24 weeks long; n=10-270; men and women, all 
ages, healthy, obese, metabolic syndrome, dyslipidemic, hypertensive, diabetic) have 
shown a significant average reduction in both TC (-5.90 mg/dL) and LDL-C (-4.95 
mg/dL) in participants consuming green tea extract (GTE) or green tea beverage (250-
2500 mg daily), compared to placebo
3,68,81
.  EGCG is of great interest as it is believed to 
be the main bioactive catechin in green tea responsible for its hypolipidemic properties, 
exerting this effect through a number of proposed mechanisms (explained previously: 
Chapter 1, section 7).   The present trial was conducted to test the reproducibility of these 
results in a group of postmenopausal women, a population of interest due to increased 
risk and incidence of dyslipidemia and related complications.  With menopause there are 
established adverse shifts in lipid metabolism, including an increase in triglycerides 
(TGs), TC, LDL-C, body mass index (BMI), central adiposity, increased waist to hip 
ratio, and a slight reduction in high-density lipoprotein cholesterol (HDL-C), after 
controlling for age
82–84
.   
This trial was a sub-study of a larger clinical trial to evaluate the effects of 
consumption of green tea extract on breast cancer biomarkers in postmenopausal women 
at high risk of breast cancer due to dense breasts.  We hypothesized that after one year, 
participants consuming green tea extract would exhibit significantly reduced levels of 
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total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and increased levels 
of high-density lipoprotein cholesterol (HDL-C).  Further sub-group analyses were 
conducted with the intention of highlighting certain populations which may respond more 
strongly to, or derive a greater benefit from, green tea consumption.  These sub-groups 
included women with baseline hypercholesterolemia (TC >240 mg/dL), women using 
statins during the study, and categorizing by baseline BMI to determine any potential 
influence of these factors on response to intervention.   
To our knowledge there have been no large-scale, long-duration (> 6 months) 
clinical trials to evaluate the impact of green tea catechins on lipid profile in 
postmenopausal women.  Significant findings in this trial may provide an additional 
option of care to practitioners in lipid risk management, using green tea extract as an 
adjunct or supplementary therapy.  Moreover, the catechin dose used in this study is in 
general widely attainable, equating to approximately 8-10 cups of green tea per day
65
.  
 
2.   Methods 
2.1   Study Population  
 
The current trial is a sub-study of the Minnesota Green Tea Study (MGTS, not yet 
published), a double-blind, randomized clinical trial. The purpose of the MGTS was to 
evaluate the effects of consumption of GTE on a number of breast cancer biomarkers, 
including mammographic density, reproductive hormones, IGF axis proteins, and 
markers of oxidative stress, in women at high risk of breast cancer due to having dense 
breasts.  From 2009-2013, 1,084 women were randomized into the study, and a total of 
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945 completed the study (12.8% withdrawal, n=139).  The MGTS was approved by the 
University of Minnesota Institutional Review Board.  The parent study (MGTS) design 
follows an intent-to-treat model (ITT), and 59 women enrolled in the study chose to stop 
taking supplement but remain in the study.  They were designated ITT and followed 
through completion as normal.  For purposes of this thesis a compliance model that did 
not include these 59 participants was used.  Thus 886 women were included in the final 
data analysis (Table 1).    Study participants were followed for one year while they 
consumed either a placebo capsule or a green tea extract (GTE) capsule containing an 
average of 320 mg total catechins (approximately 65% EGCG, 15% ECG, 10% EGC, 
10% EC).  Participants were asked to take two capsules twice per day, totaling ~1200 mg 
catechins (800 mg EGCG) per day in the treatment group.   
Mammographic density, as a primary endpoint of the MGTS, was a parameter for 
recruitment eligibility.  Potential participants diagnosed with heterogeneously or 
extremely dense breasts and at increased risk for breast cancer were sent letters of 
invitation to the parent study.  After an initial phone screening, eligible subjects went 
through an orientation session on the University of Minnesota St. Paul Campus 
(UMNSP).  All participants signed an informed consent before going forward with the 
study, and were provided with a copy for their records.  Consented participants attended a 
clinical screening for eligibility at either the Delaware Clinical Research Unit (prior to 
July 2010) or the Human Nutrition Research Clinic (HNRC, after July 2010) at UMNSP.  
The clinical screening included measurement of anthropometrics and a small non-fasting 
blood draw for genotype and hepatitis B or C exposure.  Exclusionary criteria included: 
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current smoker; use of hormone modification therapy (within the past 6 months); weight 
fluctuation of >10 pounds within the past year; experiencing a menstrual period within 
the last 12 months; diabetic; positive for hepatitis B or C; taking >10 prescription 
medications; currently taking methotrexate or Enbrel; elevated liver enzymes >1.5 upper 
limit of normal; consuming >7 alcoholic drinks per week; history of any cancer within 
the last 5 years; any history of breast cancer, ovarian cancer, or proliferative breast 
disease; BMI <18.5 or >40 kg/m
2
; and not willing to consume <1 cup of green tea per 
week.   
If eligibility was confirmed at their clinical screening, women were enrolled in the 
study.  Randomization was completed by Investigational Drug Services (IDS) at the 
University of Minnesota Medical Center, Fairview, and the randomization code was kept 
confidential from all participants and investigators during the study and analysis.  All 
supplements were dispensed by the IDS pharmacy, and both participants and 
investigators were blind to individual participant assignment throughout the entirety of 
the study.   
 
2.2   Study Design 
Nutrient and calorie intake was determined for each participant by completion of 
a Diet History Questionnaire (DHQ; National Cancer Institute) at their baseline and 
endpoint visits.  Height was measured at screening, baseline (month 0) and endpoint 
(month 12) visits.  Weight and vitals were collected at every clinic visit, and included 
systolic and diastolic blood pressure, heart rate, respirations, and temperature.  After 
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randomization, participants attended their baseline visit at the HNRC at UMNSP for 
fasting blood draws, urine collection, measurement of vitals, and to receive study 
supplement.  Baseline, month 6, and month 12 were the largest and most-involved visits, 
which included a larger fasting blood draw for biochemical assays, 24-hour urine 
collection, and completion of study questionnaires.  A comprehensive health history 
questionnaire (HHQ) was completed at the baseline visit, as well as a Menopause-
Specific Quality of Life (MENQOL) questionnaire and DHQ.  MENQOL was completed 
again at both months 6 and 12, and DHQ was repeated at month 12.  A small volume of 
blood was drawn monthly through month 6, for monitoring of liver function enzymes.  
After month 6, participants came in every three months for the remainder of the study.  
Spot urine collections were also collected at months 3 and 9, for compliance analysis.  A 
sample participant time line is shown in Figure 3 (Note: months 7, 8, 10, and 11, grayed 
out in the figure, are depicted in the timeline to maintain month sequence, however no 
regularly scheduled study visits occurred during those months).       
Serum collected at the HNRC for analysis was separated from whole blood by 
centrifugation at 1,500 g for 25 minutes, then separated into 1.5 mL aliquots and stored at 
-80 degrees Celsius until analysis.   Frozen samples were sent in batches to Quest 
Diagnostic laboratories for measurement of a standard lipid panel.   Batches were 
prepared by arranging participants in to GTE-placebo pairs, and all samples from each 
participant and pair in a batch were analyzed together in the same run.  Total cholesterol, 
HDL-C, and triglycerides were measured in serum using the Beckman Olympus AU5400 
chemistry analyzer.  LDL-C was calculated using the Friedewald method
85
.
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                                                                     Figure 3.  Sample Participant Timeline 
 
Baseline, 6 month, and 12 month: 
 Fasted blood draw 
 Questionnaires 
 24-hour urine collection 
 
Months 0 (baseline), 1, 2, 3, 4, 5, 6, 9, 12: 
Weight, vitals, liver enzymes 
Months 3, 9: Spot urine collection 
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2.3   Statistical Analyses 
Data in tables are presented as lipid concentrations in mg/dL, unless otherwise 
noted (ie: Nutrient Intake table).  Statistical analyses were performed by the study 
biostatistician; details of statistical method can be found below each table.  Successful 
randomization showed an even distribution between treatment groups for the following 
factors: dietary (soluble dietary fiber, saturated fat, dietary cholesterol, mono- and 
polyunsaturated fats, alcohol, caffeine, total kcal, and macronutrients), self-reported 
activity level, and statin use.  In all tables (except Nutrient Intake, Table 2), data are 
presented as the least squares mean and 95% confidence interval with adjustment for age 
and BMI. 
Per protocol, all reported adverse events in our study population were coded and 
monitored.  The two highest categories of participant adverse events were 
colds/infections/infestations (n=286), and gastrointestinal distress or disorders (n=260).  
Serious adverse events were rare (SAE, 2.21% of enrolled participants).  Events in this 
category included those possibly attributable to supplementation as well as those most 
likely unrelated (ie: a planned surgery).  Any participant experiencing an SAE was 
treated by an IRB-approved protocol, including being taken off supplement and 
monitored as necessary.   
 
2.4   Study Supplement 
The study supplement, Green Tea Extract Catechin Complex (Corban Complex 
GTB; abbreviated as “GTE” for use in this thesis), was manufactured and provided by 
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Corban Laboratories in Plymouth, MN.  GTE was made from green tea leaves grown by 
Youshan Tea Farm in China, and supplied by Taiyo Green Power Co. Ltd. in China. The 
decaffeinated catechin complex was prepared by a two-step ethanol extraction of dried 
green tea leaves, with the first extraction producing a crude extract to be filtered and 
concentrated.  The polyphenols were separated in the second (70%) ethanol extraction, 
concentrated, and recovered by a vacuum system.  This process was repeated 1-3 times 
before the concentrated extract was spray dried into a powder, sifted, and ready for use.  
Corban provided eight batches of green tea supplement over the course of the trial.  
Catechin composition of each batch was analyzed by two separate laboratories (Corban 
company and C.S. Yang laboratory) to ensure consistency.   A table of catechin content 
by batch can be found in Appendix: 1.  Placebo capsules were identical in appearance to 
active GTE capsules, and contained placebo (50% maltodextrin, 49.5% cellulose, 0.5% 
magnesium stearate).  All capsules were stored and dispensed by IDS based on individual 
patient schedule, and were stored in a temperature-controlled locked cabinet until given 
to participants by professional clinic staff during appropriate visits.  Participants were 
provided a three-month supply of supplement at corresponding visits: baseline, month 3, 
month 6, and month 9 (135 capsules of green tea or placebo provided for each month).  
Participants were instructed to take two pills with breakfast and two pills with dinner, 
each day.   
Each bottle contained approximately 15 extra capsules to help cover lost or 
damaged capsules, to prevent participant deviation from supplement schedule.   
Participants also received pill diaries to record when they took their supplements, to 
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facilitate tracking and compliance.  Unused pills were returned to the HNRC at 
participant’s visits, and study staff counted the remaining capsules to calculate 
compliance.  Compliance based on this method was excellent (mean: 96.5%).    
 
3.   Results 
There were no statistically significant differences between treatment and placebo 
groups for any baseline characteristics.  The GTE group did have a borderline higher 
baseline BMI (25.8 kg/m
2
 versus 25.1 kg/m
2
, P=0.072; Table 1).  The majority of the 
study population were Caucasian (~97%), held a high school or college degree (~93.5%), 
and reported regular engagement in exercise (~81%).  Though 61% of women in each 
treatment group were self-reported tea drinkers at baseline, all were asked to reduce their 
intake of green tea to <1 cup per week upon enrollment.   
There were no differences in average nutrient intake between treatment groups at 
baseline (month 0) or end of study (month 12), nor an overall treatment by time 
interaction (Table 2).  A time effect was observed, however, with both groups exhibiting 
a post-intervention decrease in all nutrient categories except MUFA, EPA, DHA, 
cholesterol, and alcohol (alcohol was borderline significantly reduced, P=.056).  The 
average reduction in daily calories after one year was -5.4%.    
Serum levels of TC, HDL-C, LDL-C, and non-HDLC showed no difference 
between groups at baseline (Table 3).  TG concentration averaged 10 mg/dL lower in the 
GTE group as compared to placebo group (P=.0007), and Chol:HDL ratio was also lower 
in the GTE group ( P=.023).  After 6 months on treatment, there were significant 
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reductions in the GTE group compared to placebo for total cholesterol (TC, P<.0001), 
HDL-C (P=.0016), LDL-C (P<.0001), and non-HDLC (P=.0004).    This significance 
remained after 12 months on treatment for TC, LDL-C, and non-HDLC, ending with 
overall average reductions of -1.79%  for TC (P<.0001), -4.15% for LDL-C (P=.0001), 
and -2.13% for non-HDLC (P<.0001).  The Chol:HDL ratio remained relatively stable 
over the course of intervention in both groups.    TG increased in the GTE group (+3.5 
mg/dL) and decreased in the placebo group (-1.7 mg/dL, P=.023) after 12 months on 
treatment.  Due to the lower baseline TGs observed in the GTE group however (GTE: 
91.8 mg/dL vs. Placebo: 101.9 mg/dL at Mo.0, P=.0007), TG levels at endpoint were 
quite similar in both groups, and did not differ significantly (P=.2897).  No treatment by 
time effects were observed for any lipid parameter (all P>.203).   
Further analysis tested the significance of the change in lipid biomarkers.  
Difference in overall change (reduction) remained significant for treatment effect in TC 
(P<.0001), LDL-C (P<.0001), and non-HDLC (P<.0001).  The change of HDL-C seen in 
the GTE group at month 6 (-1.2 mg/dL, P=.0016) was corrected by the month 12 visit    
(-0.2 mg/dL, P=.084).  However, the overall reduction of HDL-C in the GTE group, and 
overall increase in the placebo group, resulted in a significant treatment effect on HDL-C 
in a direction opposing the hypothesis (P overall for change from baseline = .004).   
Subgroup analyses were conducted to investigate six factors of interest relating to 
the overall impact of catechin supplementation.  The factors examined were baseline 
dyslipidemia (elevated TC or LDL-C and reduced HDL-C), baseline BMI, COMT 
genotype, and statin use.  Findings from previous trials on green tea effects on cholesterol 
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concentrations suggest that catechins may exert a stronger cholesterol-lowering effect in 
people who are hypercholesterolemic at baseline
59,64
.  However, the addition of a dietary 
or exercise intervention in these trials makes interpretation of the results difficult.  Our 
study design should allow for a clearer analysis of effects of GTE supplementation.  To 
measure treatment effect by baseline cholesterol, all participants were stratified into one 
of the following three clinical sub-categories, as set by the National Cholesterol 
Education Program of the National Institutes of Health
86
:  <200 mg/dL (“Desirable”), 
200-239 (“Borderline High”), > 240 mg/dL (“High”) .  Participant allocation and results 
are shown in Table 4. 
Significant reductions in TC, LDL-C, and non-HDLC were observed in the two 
lowest BMI categories (< 24.9, and 25-29.9 kg/m
2
, Table 5).  A decrease in HDL-C was 
observed in the lowest BMI category, measuring -1.6 mg/dL at midpoint and rising to -
0.4 mg/dL by endpoint (P=.03).  In contrast, a small increase in HDL-C was seen in the 
highest BMI category at month 12, though this elevation proved insignificant (+1.1 
mg/dL, P=.338).  An overall interaction was found between treatment group, BMI, and 
TG (P=.017), particularly relating to the moderate increase in TGs seen in the lowest (< 
24.9 kg/m
2
, P=.029) and highest (>30 kg/m
2
, P=.006) BMI categories (no change in TG 
in the 25-29.9 kg/m
2
 group).  Baseline BMI did not appear to effect Chol:HDL ratio 
(Table 5).   
Statin use was not restricted during the trial, and approximately 20% of study 
participants reported using statins during their enrollment (GTE: 21.2%, Placebo: 19.9%).  
The inclusion of these participants provided a unique opportunity to explore any potential 
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effects of simultaneous use of statins and GTE.  A general decrease in the impact of GTE 
was observed in those who concomittantly took statins, versus those taking the GTE 
alone (Table 6).  Within statin users, GTE versus placebo group comparisons showed a 
significant reduction of LDL-C in the GTE group at 6 months (-5.2 mg/dL, P=.011).  
This change was comparable to a similar reduction seen at 6-months in the GTE group of 
non-users (“non-users”, -6.0 mg/dL, P=.0004).  This significant reduction remained by 
month 12 in non-users (-5.9 mg/dL, P=<.0001), but waned in the statin users (-1.6 mg/dL 
at month 12, P=.133).  Significant reductions in LDL-C were seen in both statin users 
and non-users taking GTE (P=.026 and P<.0001, respectively), however the overall 
treatment effect was lessened in statin users.  Reduction of TC was borderline significant 
after 6 months in statin users taking GTE (-4.0 mg/dL, P=.051), however TC rose again 
by one year to near-baseline levels (-0.2 mg/dL, P=.344, between group comparison at 
month 12).  Curiously, TGs were the only other lipid to show a change in statin users, as 
well as the only lipid parameter to show an overall interaction between statin use and 
GTE supplementation.  By month 6, statin users taking GTE showed an average increase 
in TGs of +7.9 mg/dL (P=.021) when compared to those not taking GTE.  This trend 
continued to an average increase of +10.0 mg/dL by month 12 (P=.0145).  The difference 
between treatment groups in statin users was significant (P=.005), as was the overall 
association between TG, effect of GTE, and statin use (P=.014).  Aside from TGs, no 
additional overall interactions between treatment group, statin use, and lipid parameters, 
were seen (Table 6).      
We were also interested to see if COMT genotype influenced a participant’s  
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response to GTE supplementation.  All 886 participants were stratified in to their 
respective genotype category, and a genotype-lipid-treatment group interaction was 
analyzed (mixed model).  No significant interactions were found between COMT 
genotype and treatment effect (p values: TC=0.960, LDL-C=0.793, HDL-C=0.445, 
TG=0.943, Chol:HDLr=0.222, Non-HDLC=0.773).  Similar to the stratification for 
baseline total cholesterol sub-analysis (Table 4), baseline HDL-C and LDL-C were 
examined and analyzed.  No significant category-lipid-treatment group interactions were 
found for either of these (data not shown). 
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4.   Summary of Major Findings 
 
A. Total cholesterol (P<.0001), LDL-C (P<.0001), and non-HDLC (P<.0001) were 
significantly reduced in the GTE group after one year on treatment compared to 
placebo.  Average reductions in percent mg/dL were -1.79% (TC), -4.15% (LDL-
C) and -2.13% (non-HDLC). 
B. HDL-C decreased significantly in the GTE group by month 6 (P=.0016), and 
though it increased and was comparable to levels in the placebo group by month 
12 (P=.0836), the overall treatment effect for change from baseline was 
significant in an adverse direction (P=.0038). 
C. Average triglyceride (TG) concentration was 10 mg/dL lower in the GTE group 
than placebo group at baseline.  TGs increased in the GTE group and decreased in 
the placebo group over the course of the intervention, resulting in an overall 
significant treatment effect (P=.013) between groups despite average endpoint 
values being similar (GTE: 99.0 mg/dL vs. Placebo: 96.8 mg/dL, P=.2897). 
D. A significant overall interaction was seen between baseline cholesterol level and 
treatment effect for TC (P=0.028, Table 4).  A borderline significant interaction 
was also seen for non-HDLC (P=0.065).  
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5.   Discussion 
Previous clinical trials investigating the effect of green tea catechins on serum 
lipids have called for the need for larger, longer-duration clinical trials to verify or refute 
earlier findings
32,57,59,65
.  The results of our study provide evidence to support the ability 
of green tea catechins to reduce total cholesterol (-4.6 mg/dL, P=<.0001), LDL-C (-5.0 
mg/dL, P=<.0001), and non-HDLC (-4.4 mg/dL, P=<.0001) in postmenopausal women.  
Circulating estradiol has been positively associated with HDL-C, and negatively 
associated with TC and LDL-C
87
.  Thus, these are significant findings as menopause is 
independently associated with adverse changes in lipid profile
82,83,88
.  A borderline 
significant decrease in the Chol:HDL ratio was seen in the GTE group after one year on 
treatment, versus no change in the placebo group.  This is of interest to note, as chol:HDL 
ratio can be used clinically as an indicator for cardiovascular risk as well
86
.  The final 
concentrations of HDL-C in the treatment group were not significantly different than the 
placebo group.  However due to the opposing trend seen at the month 6 time point (GTE: 
-1.2 mg/dL, Placebo: +0.6 mg/dL, P=.0016), the overall treatment effect was deemed 
significant (change in HDL-C from baseline: P=.004).  Our study demonstrated 
supplementation with GTE for one year resulted in significant overall reductions in TC, 
LDL-C, and non-HDLC.   
 In the first sub-analysis (Table 4), overall treatment effect by baseline TC 
category was examined.  The largest (magnitude) improvement in any lipid parameter in 
our study was the change in TC concentration seen after one year on GTE in women with 
a baseline cholesterol level of >240 mg/dL (considered “high” by NCEP standards).  
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Though reductions in TC, LDL-C, and non-HDL-C were also seen in the placebo group 
in this category, the overall change in in the >240 group (-23.0 mg/dL, P=.0012) is still 
striking and shown to be significant.  TC was significantly reduced in the 200-240 group 
(-7.4 mg/dL overall, P=.0001) and the <200 group (+4.2 mg/dL, P=.065) as well.  
Likewise, LDL-C was significantly reduced in the >240 mg/dL baseline group (-20.7 
mg/dL, P=.007) and 200-240 mg/dL group (-6.6 mg/dL P<.0001), and LDL-C increased 
slightly in the <200 mg/dL group (+1.7 mg/dL, P=.024).  A thorough review by M.C. 
Houston on non-pharmacologic therapies for dyslipidemia suggests that similar to green 
tea catechins, a number of compounds appear to reduce cholesterol or triglycerides more 
effectively in hyperlipidemic participants, such as dietary/soluble fiber
89
 and omega-3 
fish oils
90
.  A similar association has been reported for statins as well
91
.  
BMI and lipids have been shown to be positively correlated as well, particularly 
related to TC and LDL-C
82
.  Given the suggested increase in efficacy of catechins in 
hypercholesterolemic groups, we felt it was plausible to explore this effect by BMI.  
Changes in lipid profile for the lowest BMI category (<24.9 kg/m
2
) tended to follow the 
trend of the other two categories, though change in levels were often less pronounced.  
Women in the highest BMI category (>30 kg/m
2
) exhibited larger magnitudes of change, 
in both GTE and placebo groups, so no significant interactions were shown for this 
category except a rise in TGs in the GTE group after one year on treatment (+6.0 mg/dL, 
P=.0064).  The only lipid parameter to show an overall interaction between treatment 
group and statin use were triglycerides (TG).  After one year on GTE treatment, TGs rose 
+10.0 mg/dL in statin users (P=0145), though only +1.8 mg/dL in non-users (P=.244).  
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The average TG level at baseline was 101.9 mg/dL in the placebo group, and 91.8 mg/dL 
in the GTE group (.P=0007), thus the +10.0 mg/dL increase in TG seen with GTE+statin 
supplementation brought both groups to a similar endpoint concentration by month 12.  
This is surprising because combination therapy is sometimes used to help maximize a 
patient’s response to or efficacy of a treatment.  For example, nicotinic acid may be 
prescribed to increase HDL-C in a patient who is also taking a statin to decrease LDL-C.  
Additional combinations may include a concomitant use of plant sterol/stanols, soluble 
fiber, statin, fish oil, or bile acid sequestrants, all of which have been independently 
associated, to varying degrees, with lipid profile improvement
89
.  Adverse diet-drug 
interactions are also known to exist however, such as the inhibitory effect of grapefruit 
juice on statin metabolism
92
.  Though slight increases in TG have been shown in some 
previous green tea and lipid clinical trials, the greater potency of TG-reduction by statins 
would be expected to override that.  Somewhat complicating this however, is paper by 
Stein et al. which showed statins effectively reduced triglyceride levels, though only in 
patients who were hyperlipidemic at baseline
91
.  It is possible this is why no triglyceride-
lowering effect was seen in the GTE, since baseline levels were already low.      
This was not a mechanistic study, and the exact nature of this interaction is not 
fully understood.  It has been suggested the degradation of green tea catechins in the high 
pH of the small intestine decreases their overall absorption and bioavailability
10,93
.  An in 
vitro study by Green and colleagues tested the stabilizing effects of various additives, 
including grapefruit juice, to green tea in a simulated small intestine environment.  The 
addition of a grapefruit juice+catechin mixture to the simulated intestine increased the 
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recovery (post-digestion presence) of full catechins from <20% to 61% 
93
.  Assuming 
these results translate to greater in vivo bioavailability would be inappropriate, however it 
highlights the need to be open to unexpected interactions, including any potential diet-
catechin-drug interactions. 
Participants were also separated into groups based on their COMT genotype (A/A: 
low-activity, A/G: intermediate-activity, G/G: high-activity), an enzyme involved in 
catechin metabolism.  Previous studies have suggested carriers of the low-activity COMT 
allele may derive more benefit from consuming green tea, due to the decreased enzyme 
activity and thus slower excretion of catechins from the body
94,95
.  However, if reduced 
intestinal absorption of lipids is indeed the primary mechanism by which green tea 
catechins exert their hypolipidemic effects, it is understandable that the COMT enzyme 
would have little effect on this process, as the action would take place before the 
catechins would be metabolized.   
Strengths of the current study include having a large study population (n=886), 
high compliance to treatment (mean: 96.5%), and being an extended intervention trial (12 
months) with a well-executed, rigorous study design (randomized, double-blind, placebo-
controlled).  The treatment being tested was a concentrated catechin extract of Chinese 
green tea leaves, equating to approximately 8-10 cups of brewed green tea per day.  
Though some constituents of the whole leaf are lost in a catechin extraction (ie: vitamins, 
amino acids, fiber, minerals), this method provides more control over treatment amount 
and helps to reduce the variability in daily catechin intake that may happen if participants 
were asked to brew their own tea.  Additionally, some studies have demonstrated 
  53 
enhanced catechin absorption and bioactivity with green tea extract capsules as compared 
to similar amounts provided in brewed green tea
96
.  Our use of an encapsulated green tea 
extract in this trial also helped encourage compliance, and allowed for successful 
blinding of treatments.   
Limitations of this study include a lack of diversity in race/ethnicity, and the self-
reported data on medication use and health history, physical activity habits, and dietary 
intake of nutrients.  Although participants were asked to maintain stable body weight, 
consume four study capsules per day, and to inform study staff of any changes in 
medication, the integrity of this data is reliant on their compliance to our requests.  
Participants were expected to come to blood-draws in a fasted state, and unless gross 
lipemia was seen during processing of their blood work, it was believed the participant 
was fasting.  Non-compliance with fasting requirements for blood draws was not believed 
to be an issue during sample collection.  Participants often self-reported if they had 
consumed anything prior to their blood draw (ie: coffee), and if they had, they were asked 
to re-schedule and return fasting at a later date.  Though fasting is more important for 
triglyeride and LDL-C measurement (which can be underestimated in a non-fasting blood 
sample), TC, HDL-C, Non-HDL, and Chol:HDL ratio are essentially unaffected by 
fasting status
97
.  Even so, the large sample size of our population is likely to neutralize an 
overall impact of any occasional non-fasting lipid panel.  Our biochemical assays were 
also based on a single sample collection for each time point, though the use of an 
automated chemistry analyzer for the lipid panels helped to maintain consistency of 
testing protocol and accuracy.     
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As shown in Table 1, the majority of our study population was Caucasian.  This 
is possibly a consequence of the centers used for recruitment for the parent study, 
primarily located in the University and suburban neighborhoods of Minneapolis and St. 
Paul.  Worth noting, a smaller (n=103) study from 2012 of very similar design to the 
current trial, reported similar trends in lipid change in a majority Hispanic population 
(53% of participants)
65
.  These limitations may somewhat reduce our ability to 
extrapolate these results to a general population, however we believe the underlying trend 
in the results is promising.    
In conclusion, consuming 1200 mg GTE (800 mg as EGCG) for one year 
significantly reduced total cholesterol (-4.6 mg/dL, P=<.0001), LDL-cholesterol (-5.0 
mg/dL, P<.0001), and non-HDL cholesterol (-4.4 mg/dL, P<.0001) in postmenopausal 
women.  Triglycerides rose in women taking both GTE and statins, as well as overall 
with GTE supplementation.  In the overall analysis by treatment effect, TGs were raised 
an average of +3.5 mg/dL (P=.0133) after one year, though the underlying mechanism 
responsible for this increase has yet to be elucidated.   A small but significant decrease in 
HDL-C was observed in the GTE supplement group after six months (-1.2 mg/dL, 
P=.0016), returning to near normal after one year though remaining statistically 
significant (-0.2 mg/dL, P=.0038).  A generally stronger lipid-modifying effect was seen 
at the 6 month time point, with mild to moderate attenuation in some parameters by 
month 12.  Exploratory subgroup analyses showed GTE had the greatest and most 
favorable impact on serum lipids in women with a baseline total cholesterol >240 mg/dL.   
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This study was a well-designed, placebo-controlled clinical intervention 
demonstrating a strong association between consumption of a green tea catechin extract 
and reduction of total, LDL-, and non-HDL cholesterol in postmenopausal women.  
Research into dosing guidelines, possible drug interactions, and reproducibility in 
hypercholesterolemic patients, would be beneficial, to further the potential therapeutic 
use of these findings.          
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6.   Tables 
 
Table 1.  Baseline demographic and lifestyle variables by treatment group. 
 
 1From t-test for continuous variables and χ2 test for categorical variables. 
 
 
 
 
 
      Variable 
GTE: 
(n=429) 
Placebo: 
(n=457) 
P value1 
Age (SD), years 
 
59.9 (5.0) 
 
59.6 (5.0) 
 
0.362 
 
BMI (SD), kg/m
2
 25.8 (7.8) 25.1 (3.6) 0.072 
Race    
     White, n (%) 418 (97.4) 441 (96.5) 0.481 
Education    
     College or High, n (%) 400 (93.9) 423 (93.4) 0.753 
Ever smoking    
     Yes,  n  (%) 139 (32.4) 142 (31.1) 0.739 
Alcohol drinking    
     Yes,  n  (%) 340 (79.3) 380 (83.2) 0.268 
Tea drinking    
     Yes,  n  (%) 263 (61.5) 283 (62.2) 0.228 
Regular exercise    
     Yes, n  (%) 347 (80.9) 372 (81.4) 0.957 
Taking aspirin    
     Yes,  n  (%) 25 (5.8) 31 (6.8) 0.559 
Taking statins    
     Yes,  n  (%) 91 (21.2) 91 (19.9) 0.632 
Total energy intake (SD), 
kcal 
1435 (545) 1443 (530) 0.809 
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Table 2.   Nutrient Intake at Month 0 (baseline) & Month 12 (endpoint) by Treatment Group.
1
 
Nutrient, 
Time Point 
GTE:  n=428 
Mean (SD) 
Placebo:  n=455 
Mean (SD) 
 
 
Visit
2 
P values 
 
Trt
3
 
 
 
Time
3 
 
 
Total Energy (kcal) 
    Month 0  
    Month 12 
 
 
 
1436 (1384.9-1486.0) 
1361 (1314-1408.3) 
 
 
 
1441 (1391.8-1490.0) 
1360 (1314.5-1405.0) 
 
 
 
0.8825 
0.9770 
 
 
0.9519 
 
 
<.0001 
Carbohydrate (g) 
    Month 0  
    Month 12 
 
179.6 (172.9-186.2) 
168.4 (162.2-174.5) 
 
181.4 (175-187.9) 
167.6 (161.6-173.5) 
 
0.6901 
0.8534 
0.9031 <.0001 
Protein (g) 
    Month 0  
    Month 12 
 
58.7 (56.5-60.8) 
55.7 (53.6-57.7) 
 
57.4 (55.3-59.5) 
54.6 (52.6-56.6) 
 
0.4278 
0.4781 
0.4132 <.0001 
Total Fat (g) 
    Month 0  
    Month 12 
 
52.9 (50.5-55.3) 
51.7 (49.5-53.9) 
 
53.7 (51.4-56) 
52.0 (49.8-54.2) 
 
0.6368 
0.8456 
0.7182 0.0272 
Saturated Fat (g) 
    Month 0  
    Month 12 
 
16.2 (15.5-16.9) 
15.9 (15.2-16.6) 
 
16.4 (15.7-17.1) 
15.8 (15.2-16.5) 
 
0.7328 
0.8393 
0.9356 0.0269 
MUFA (g) 
    Month 0  
    Month 12 
 
20.5 (19.5-21.5) 
20.1 (19.2-21) 
 
20.8 (19.9-21.8) 
20.4 (19.5-21.3) 
 
0.6751 
0.5894 
0.6081 0.1240 
PUFA (g) 
    Month 0  
    Month 12 
 
12.2 (11.6-12.8) 
11.9 (11.3-12.5) 
 
12.5 (11.9-13.1) 
11.9 (11.4-12.5) 
 
0.4712 
0.8787 
0.6249 0.0162 
Omega-3 FAs (g) 
  EPA (20:5) 
    Month 0  
    Month 12 
 
 
0.0 (0-0) 
0.0 (0-0) 
 
 
0.0 (0-0) 
0.0 (0-0) 
 
 
0.6981 
0.6328 
 
 
 
0.6171 
 
 
 
0.4182 
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1
 Data is presented in mean (95% CI); adjusted for Age and BMI. 
2
 Test for difference between treatment and placebo group by time point using ANCOVA (GLM). 
3 
Test for overall difference between treatment groups, and change over time, using mixed  
  methods for repeated measures data.   
  Abbreviations: MUFA (monounsaturated fatty acid), PUFA (polyunsaturated fatty acid), FA (fatty  
  acid), EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid), ALA (α-linolenic acid), Total  
  Fiber = Total Dietary Fiber. 
  DHA (22:6) 
    Month 0  
    Month 12 
  ALA (18:3) 
    Month 0  
    Month 12 
 
 
 
0.0 (0-0.1) 
0.0 (0-0.1) 
 
 
 
1.0 (1-1.1) 
1.0 (0.9-1) 
 
 
 
0.0 (0-0.1) 
0.0 (0-0) 
 
 
 
1.0 (1-1.1) 
1.0 (0.9-1) 
 
 
 
0.6055 
0.7070 
 
0.6594 
0.7409 
 
0.6009 
 
 
 
0.9434 
 
0.1410 
 
 
 
<.0001 
 
 
Trans-FA (g) 
    Month 0  
    Month 12 
 
 
 
2.7 (2.6-2.8) 
2.6 (2.5-2.7) 
 
 
 
2.7 (2.5-2.8) 
2.5 (2.4-2.7) 
 
 
 
0.7925 
0.3204 
 
 
0.5005 
 
 
0.0041 
Cholesterol (mg) 
    Month 0  
    Month 12 
 
 
145.5 (138.6-152.3) 
141.3 (134.5-148) 
 
 
142.1 (135.5-148.8) 
140.2 (133.6-146.8) 
 
 
0.4986 
0.8321 
0.6275 0.1077 
Total Fiber (g) 
    Month 0  
    Month 12 
 
17.6 (16.8-18.3) 
16.7 (16-17.4) 
 
17.6 (16.9-18.4) 
16.4 (15.7-17.1) 
 
0.9442 
0.4948 
0.7524 <.0001 
Soluble Fiber (g) 
    Month 0  
    Month 12 
 
5.8 (5.5-6.1) 
5.5 (5.3-5.8) 
 
5.8 (5.6-6.1) 
5.4 (5.2-5.7) 
 
0.8542 
0.5449 
0.8359 <.0001 
Caffeine (mg) 
    Month 0  
    Month 12 
 
358.3 (327.9-388.7) 
337.3 (308.8-365.9) 
 
379.0 (349.6-408.5) 
361.1 (333.4-388.8) 
 
0.3371 
0.2416 
0.2569 0.0046 
Alcohol (g) 
    Month 0  
    Month 12 
 
7.0 (5.8-8.2) 
5.8 (5-6.6) 
 
6.5 (5.4-7.7) 
6.2 (5.5-7) 
 
0.5927 
0.4296 
0.9785 0.0564 
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Table 3.  Mean level and change of blood lipids by treatment group and time point. 
Measure
 
(mg/dL)
1
 
GTE:  n=429 Placebo:  n=455 P 
3
 
Overall 
Trt
4 
Time
4
 
 
 
TC 
    Value at Mo.0  
    Value at Mo.6
2
 
      Change from 0 
    Value at Mo.12
2
 
      Change from 0 
    P (actual value) 
    P (change) 
 
 
 
 
 
 
 
 
 
 
 
 
 
206.5 (203.6-209.5) 
200.8 (199-202.7) 
-6.6 (-8.6-4.7) 
202.8 (200.9-204.8) 
-4.6 (-6.7-2.5) 
 
 
 
 
 
 
 
 
 
 
 
 
208.8 (205.9-211.7) 
207.7 (205.9-209.5) 
-0.3 (-2.2-1.6) 
209.5 (207.6-211.4) 
1.6 (-0.5-3.6) 
 
 
 
 
 
 
 
 
 
 
 
 
0.2760 
<.0001 
<.0001 
<.0001 
<.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<.0001 
<.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.0068 
0.0068 
HDL 
    Value at Mo.0  
    Value at Mo.6
2
 
      Change from 0 
    Value at Mo.12
2
 
      Change from 0 
    P (actual value) 
    P (change) 
 
 
70.2 (68.5-71.9) 
68.4 (67.7-69.2) 
-1.2 (-2-0.4) 
69.4 (68.6-70.1) 
-0.2 (-1-0.6) 
 
68.9 (67.3-70.5) 
70.0 (69.3-70.7) 
0.6 (-0.2-1.3) 
70.2 (69.4-70.9) 
0.8 (0-1.5) 
 
0.2778 
0.0028 
0.0016 
0.1306 
0.0836 
 
 
 
 
 
 
0.0071 
0.0038 
 
 
 
 
 
 
0.0416 
0.0405 
TG 
    Value at Mo.0  
    Value at Mo.6
2
 
      Change from 0 
    Value at Mo.12
2
 
      Change from 0 
    P (actual value) 
    P (change) 
 
91.8 (87.7-96) 
98.2 (95.5-101) 
2.0 (-0.9-4.8) 
99.0 (96.1-102) 
3.5 (0.3-6.7) 
 
101.9 (97.9-105.9) 
96.4 (93.7-99.1) 
-1.4 (-4.1-1.4) 
96.8 (93.9-99.7) 
-1.7 (-4.8-1.4) 
 
0.0007 
0.3628 
0.0987 
0.2897 
0.0232 
 
 
 
 
 
 
0.1920 
0.0133 
 
 
 
 
 
 
0.6438 
0.6454 
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1
 Data is presented in mean (95% CI); adjusted for Age and BMI. 
2
 Adjusted for Age, BMI, and baseline lipid value, for that parameter (ie: HDL measured value at     
  Month 6 and Month 12 adjusted for baseline HDL). 
3 
Test for treatment effect between GTE and placebo groups at time point using ANCOVA (GLM). 
LDL  
    Value at Mo.0  
    Value at Mo.6
2
 
      Change from 0 
    Value at Mo.12
2
 
      Change from 0 
    P (actual value) 
    P (change) 
 
 
118.0 (115.3-120.6) 
112.3 (109.6-114.9) 
-5.8 (-7.5-4.1) 
113.1 (110.5-115.7) 
-5.0 (-6.8-3.1) 
(Placebo: n=454)* 
119.5 (116.9-122.1) 
118.9 (116.4-121.5) 
-0.5 (-2.1-1.2) 
120.4 (117.9-123) 
1.1 (-0.7-2.9) 
 
0.4204 
0.0004 
<.0001 
0.0001 
<.0001 
 
 
 
 
 
 
<.0001 
<.0001 
 
 
 
 
 
 
0.0610 
0.0571 
Chol:HDL ratio 
    Value at Mo.0  
    Value at Mo.6
2
 
      Change from 0 
    Value at Mo.12
2
 
      Change from 0 
    P (actual value) 
    P (change) 
 
 
3.1 (3-3.2) 
3.1 (3.1-3.1) 
-0.1 (-0.1-0) 
3.1 (3-3.1) 
-0.1 (-0.1-0) 
 
3.2 (3.2-3.3) 
3.1 (3.1-3.2) 
0.0 (-0.1-0) 
3.2 (3.1-3.2) 
0.0 (-0.1-0) 
 
0.0231 
0.0577 
0.2576 
0.0210 
0.2117 
 
 
 
 
 
 
0.0137 
0.1696 
 
 
 
 
 
 
0.9099 
0.9046 
Non-HDLC 
    Value at Mo.0  
    Value at Mo.6
2
 
      Change from 0 
    Value at Mo.12
2
 
      Change from 0 
    P (actual value) 
    P (change) 
 
136.3 (133.4-139.2) 
132.4 (130.6-134.1) 
-5.4 (-7.3--3.6) 
133.4 (131.5-135.3) 
-4.4 (-6.4-2.4) 
 
139.9 (137.1-142.7) 
137.7 (136-139.3) 
-0.9 (-2.6-0.9) 
139.4 (137.5-141.2) 
0.8 (-1.2-2.7) 
 
0.0837 
<.0001 
0.0004 
<.0001 
0.0003 
 
 
 
 
 
 
<.0001 
<.0001 
 
 
 
 
 
 
0.0446 
0.0453 
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4 
Test for overall treatment, time, and treatment by time, effects between GTE and placebo     
  groups using mixed methods for repeated measures. 
* LDL values could not be calculated for one participant due to triglyceride levels >400 mg/dL.  
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Table 4.  Treatment Effect: by Baseline Total Cholesterol (TC) Category 
Measure
 
& 
 
Group (n)
1
 
Time point Overall P values: 
change Mo.0 to 
Mo.6 (mg/dL) 
change Mo.0 to 
Mo.12 (mg/dL) 
Trt
3
 Time
3 Trt* 
Time
3 Interaction
4
 
 
TC  
  <200 mg/dL      
     GTE (181) 
     Placebo (184) 
     P
2 
  200-240 mg/dL 
    GTE (191) 
     Placebo (204) 
     P
2
  
  >240 mg/dL 
     GTE (57) 
     Placebo (67) 
     P
2 
 
 
 
0.2 (-2.6-3) 
4.5 (1.8-7.3) 
0.0314 
 
-9.3 (-12.1-6.5) 
-1.5 (-4.2-1.2) 
<.0001 
 
 
 
 
 
 
 
-19.4 (-25.4-13.3) 
-10.2 (-15.8-4.6) 
0.0338 
 
 
 
4.2 (1.2-7.2) 
6.5 (3.5-9.4) 
0.2792 
 
-7.4 (-10.2-4.6) 
-0.1 (-2.8-2.6) 
0.0003 
 
 
 
 
 
 
 
-23.0 (-29.6-16.4) 
-7.0 (-13.1-1) 
0.0007 
 
 
 
 
 
0.0652 
 
 
 
<.0001 
 
 
 
0.0012 
 
 
 
 
 
 
 
0.0038 
 
 
 
0.1296 
 
 
 
0.9402 
 
 
 
 
 
0.3683 
 
 
 
0.8220 
 
 
 
0.2354 
 
 
0.028 
 
HDL 
  <200 mg/dL 
     GTE 
     Placebo 
     P
2 
  200-240 mg/dL 
     GTE 
     Placebo 
     P
2
  
  >240 mg/dL 
     GTE 
     Placebo 
     P
2 
 
 
 
0.0 (-1.2-1.2) 
1.7 (0.5-2.9) 
0.0464 
 
-2.1 (-3.3-0.9) 
-0.3 (-1.5-0.9) 
0.0421 
 
 
 
 
-2.1 (-3.8-0.4) 
0.1 (-1.5-1.7) 
0.0715 
 
 
 
1.4 (0.2-2.7) 
1.2 (0-2.4) 
0.8035 
 
-1.4 (-2.6-0.3) 
0.4 (-0.7-1.5) 
0.0215 
 
 
 
 
-1.3 (-3.7-1.1) 
0.7 (-1.5-2.9) 
0.2404 
 
 
 
 
 
0.3085 
 
 
 
0.0106 
 
 
 
0.0663 
 
 
 
 
 
0.3043 
 
 
 
0.1111 
 
 
 
0.4565 
 
 
 
 
 
 
0.0303 
 
 
 
0.9522 
 
 
 
0.9521 
 
 
 
0.535 
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TG  
  <200 mg/dL 
     GTE 
     Placebo 
     P
2 
  200-240 mg/dL 
     GTE 
     Placebo 
     P
2
  
  >240 mg/dL 
     GTE 
     Placebo 
     P
2 
 
 
 
 
 
 
4.9 (0.7-9.1) 
-2.1 (-6.3-2) 
0.0204 
 
3.0 (-1.2-7.2) 
-1.4 (-5.5-2.7) 
0.1469 
 
-9.3 (-17.7-0.9) 
-0.4 (-8.2-7.4) 
0.1334 
 
 
 
 
5.2 (1-9.4) 
1.0 (-3.1-5.1) 
0.1615 
 
3.2 (-1.2-7.7) 
-2.7 (-7-1.6) 
0.0615 
 
-2.5 (-15.9-11) 
-5.0 (-17.4-7.4) 
0.7864 
 
 
 
 
 
0.0281 
 
 
 
0.0411 
 
 
 
0.6416 
 
 
 
 
 
0.2661 
 
 
 
0.7652 
 
 
 
0.8275 
 
 
 
 
 
0.5012 
 
 
 
0.6148 
 
 
 
0.1973 
 
 
 
0.139 
 
LDL 
  <200 mg/dL 
     GTE 
     Placebo 
     P
2 
  200-240 mg/dL 
     GTE 
     Placebo 
     P
2
  
  >240 mg/dL 
     GTE (57) 
     Placebo (66*) 
     P
2
 
 
 
 
 
-0.7 (-3.2-1.7) 
3.3 (0.9-5.7) 
0.0235 
 
-7.8 (-10.2-5.4) 
-0.9 (-3.2-1.4) 
<.0001 
 
-15.4 (-20.9-10) 
-9.7 (-14.8-4.6) 
0.1400 
 
 
 
 
1.7 (-1-4.4) 
5.1 (2.4-7.8) 
0.0847 
 
-6.6 (-9-4.2) 
0.0 (-2.3-2.4) 
0.0002 
 
-20.7 (-26.9-14.6) 
-7.2 (-12.9-1.5) 
0.0021 
 
 
 
 
 
0.0245 
 
 
 
<.0001 
 
 
 
0.0066 
 
 
 
 
 
0.0138 
 
 
 
0.2576 
 
 
 
0.5015 
 
 
 
 
 
0.8183 
 
 
 
0.9127 
 
 
 
0.1163 
 
 
 
0.142 
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Chol:HDLratio 
  <200 mg/dL 
     GTE 
     Placebo 
     P
2 
  200-240 mg/dL 
     GTE 
     Placebo 
     P
2
  
  >240 mg/dL 
     GTE 
     Placebo 
     P
2
 
 
 
 
 
 
0.0 (-0.1-0.1) 
0.0 (-0.1-0.1) 
0.6853 
 
-0.1 (-0.1-0) 
0.0 (-0.1-0) 
0.3047 
 
-0.2 (-0.3-0.1) 
-0.1 (-0.3-0) 
0.5940 
 
 
 
 
 
0.0 (-0.1-0.1) 
0.1 (0-0.1) 
0.1121 
 
-0.1 (-0.1-0) 
-0.1 (-0.1-0) 
0.9681 
 
-0.3 (-0.5-0.1) 
-0.2 (-0.3-0) 
0.4106 
 
 
0.2685 
 
 
 
0.5576 
 
 
 
0.4588 
 
 
0.2370 
 
 
 
0.5961 
 
 
 
0.4793 
 
 
0.1814 
 
 
 
0.3640 
 
 
 
0.8300 
0.754 
 
Non-HDLC 
  <200 mg/dL 
     GTE 
     Placebo 
     P
2 
  200-240 mg/dL 
     GTE 
     Placebo 
     P
2
  
  >240 mg/dL 
     GTE 
     Placebo 
     P
2
 
 
 
 
 
0.2 (-2.4-2.9) 
2.8 (0.2-5.5) 
0.1720 
 
-7.2 (-9.7-4.7) 
-1.2 (-3.6-1.3) 
0.0009 
 
-17.3 (-23-11.6) 
-10.3 (-15.6-5.1) 
0.0836 
 
 
 
 
2.7 (-0.2-5.6) 
5.3 (2.4-8.1) 
0.2154 
 
-5.9 (-8.6-3.2) 
-0.5 (-3.1-2.1) 
0.0048 
 
-21.7 (-28.7-14.8) 
-7.7 (-14.1-1.3) 
0.0047 
 
 
 
 
 
 
0.1420 
 
 
 
0.0003 
 
 
 
 
 
 
 
 
 
 
 
0.0072 
 
 
 
 
 
 
0.0074 
 
 
 
0.3422 
 
 
 
 
 
 
 
 
 
 
 
0.7229 
 
 
 
 
 
 
0.9843 
 
 
 
0.7839 
 
 
 
 
 
 
 
 
 
 
 
0.2365 
 
 
 
 
 
0.065 
1
 Data is presented in mean (95% CI); adjusted for Age and BMI. 
2
 Test for treatment effect between GTE and placebo groups at time point using ANCOVA (GLM). 
3 
Test for overall treatment, time, and treatment by time, effects between GTE and placebo  
  groups using mixed methods for repeated measures. 
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4 
Test for overall interaction between treatment group and stratified variables using mixed  
  methods for repeated measures. 
* LDL values could not be calculated for one participant due to triglyceride levels >400 mg/dL. 
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Table 5.  Treatment Effect: by Baseline BMI Category 
Measure 
(kg/m
2
) & 
 
Group (n)
1
 
Time point Overall P values: 
change Mo.0 to 
Mo.6 (mg/dL) 
change Mo.0 to 
Mo.12 (mg/dL) 
Trt
3
 Time
3 Trt* 
Time
3 Interaction
4
 
 
TC 
  < 24.9       
     GTE (213) 
     Placebo (238) 
     P*
 
  25-29.9 
    GTE (158) 
     Placebo (175) 
     P*  
  > 30 
     GTE (58) 
     Placebo (42) 
     P* 
 
 
 
 
-6.4 (-9.1-3.8) 
-0.9 (-3.4-1.6) 
0.0030 
 
-6.2 (-9.7-2.8) 
0.9 (-2.4-4.1) 
0.0033 
 
 
 
-9.1 (-14.5-3.8) 
-1.5 (-7.7-4.8) 
0.0716 
 
 
 
 
-4.2 (-7.2-1.3) 
1.4 (-1.4-4.1) 
0.0071 
 
-5.4 (-8.7-2) 
3.5 (0.3-6.7) 
0.0002 
 
 
 
-4.2 (-10.2-1.8) 
-5.0 (-12-2.1) 
0.8741 
 
 
0.0011 
 
 
 
 
 
 
 
0.0002 
 
 
 
 
 
0.3628 
 
 
 
 
0.0254 
 
 
 
 
 
0.1393 
 
 
 
 
 
0.7764 
 
 
0.9635 
 
 
 
 
 
0.4584 
 
 
 
 
 
0.0786 
 
0.556 
 
HDL 
  < 24.9       
     GTE  
     Placebo  
     P*
 
  25-29.9 
    GTE  
     Placebo  
     P*  
  > 30 
     GTE  
     Placebo  
     P* 
 
 
 
-1.6 (-2.8-0.4) 
0.2 (-1-1.3) 
0.0376 
 
-0.7 (-1.9-0.5) 
0.8 (-0.3-2) 
0.0665 
 
 
 
-1.2 (-2.7-0.4) 
1.6 (-0.2-3.5) 
0.0260 
 
 
 
-0.4 (-1.5-0.7) 
0.9 (-0.1-2) 
0.0994 
 
-0.5 (-1.7-0.7) 
0.5 (-0.6-1.7) 
0.2414 
 
 
 
1.1 (-1.5-3.7) 
1.1 (-2-4.1) 
0.9874 
 
 
0.0299 
 
 
 
 
 
0.0644 
 
 
 
 
0.3375 
 
 
 
 
0.0139 
 
 
 
 
 
0.9208 
 
 
 
 
0.3527 
 
 
0.6003 
 
 
 
 
 
0.5952 
 
 
 
 
0.1235 
 
0.980 
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TG 
  < 24.9       
     GTE  
     Placebo  
     P*
 
  25-29.9 
    GTE  
     Placebo  
     P*  
  > 30 
     GTE  
     Placebo  
     P* 
 
 
 
 
3.2 (-0.2-6.6) 
-1.8 (-5.1-1.4) 
0.0368 
 
-1.0 (-6.2-4.2) 
0.9 (-4-5.9) 
0.5941 
 
 
 
5.4 (-3.5-14.2) 
-7.8 (-18.2-2.7) 
0.0633 
 
 
 
 
4.3 (0.6-8.1) 
0.0 (-3.5-3.6) 
0.1020 
 
1.4 (-4.4-7.1) 
-0.7 (-6.1-4.8) 
0.6182 
 
 
 
6.0 (-5.4-17.4) 
-15.7 (-29.1--2.3) 
0.0179 
 
 
0.0287 
 
 
 
 
0.9899 
 
 
 
 
 
0.0064 
 
 
 
 
0.2530 
 
 
 
 
0.8699 
 
 
 
 
 
0.4755 
 
 
0.8133 
 
 
 
 
0.4201 
 
 
 
 
 
0.4115 
 
0.017 
 
LDL 
  < 24.9      
     GTE  
     Placebo  
     P*
 
  25-29.9 
    GTE 
     Placebo (174) 
     P*  
  > 30 
     GTE 
     Placebo 
     P* 
 
 
 
 
-5.4 (-7.6-3.2) 
-0.6 (-2.7-1.5) 
0.0022 
 
-5.3 (-8.3-2.3) 
0.2 (-2.7-3) 
0.0105 
 
 
 
-9.0 (-14.2-3.9) 
-1.6 (-7.6-4.5) 
0.0694 
 
 
 
 
-4.7 (-7.3-2.1) 
0.4 (-2-2.9) 
0.0046 
 
-5.2 (-8.2-2.1) 
3.0 (0.1-5.9) 
0.0002 
 
 
 
-5.7 (-11.3--0.1) 
-2.9 (-9.5-3.6) 
0.5340 
 
 
0.0007 
 
 
 
 
0.0004 
 
 
 
 
 
0.1482 
 
 
 
 
0.2923 
 
 
 
 
0.1215 
 
 
 
 
 
0.6988 
 
 
0.8511 
 
 
 
 
0.1700 
 
 
 
 
 
0.2995 
 
0.768 
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Chol:HDLratio 
  < 24.9      
     GTE  
     Placebo  
     P*
 
  25-29.9 
    GTE  
     Placebo  
     P*  
  > 30 
     GTE  
     Placebo  
     P* 
 
 
 
0.0 (-0.1-0) 
0.0 (-0.1-0) 
0.4128 
 
-0.1 (-0.2-0) 
0.0 (-0.1-0.1) 
0.2926 
 
 
-0.1 (-0.3-0) 
-0.2 (-0.3-0) 
0.6835 
 
 
 
-0.1 (-0.1-0) 
0.0 (-0.1-0) 
0.1966 
 
-0.1 (-0.1-0) 
0.0 (-0.1-0.1) 
0.2637 
 
 
-0.1 (-0.3-0.1) 
-0.3 (-0.5-0) 
0.4232 
 
 
0.2186 
 
 
 
 
 
 
0.2067 
 
 
 
 
 
0.4597 
 
 
 
 
0.8287 
 
 
 
 
 
 
0.6616 
 
 
 
 
 
0.4667 
 
 
0.5616 
 
 
 
 
 
 
0.8829 
 
 
 
 
 
0.5834 
0.416 
 
Non-HDLC 
  < 24.9        
     GTE  
     Placebo  
     P*
 
  25-29.9  
    GTE  
     Placebo  
     P*  
  > 30 
     GTE  
     Placebo  
     P* 
 
 
 
-4.8 (-7.2-2.4) 
-1.0 (-3.3-1.2) 
0.0241 
 
-5.5 (-8.8-2.3) 
0.0 (-3-3.1) 
0.0148 
 
 
-8.0 (-13.2-2.7) 
-3.1 (-9.3-3.1) 
0.2434 
 
 
 
-3.9 (-6.7-1.1) 
0.4 (-2.2-3.1) 
0.0289 
 
-4.9 (-8.2-1.6) 
2.9 (-0.2-6) 
0.0008 
 
 
-5.3 (-11.5-0.9) 
-6.0 (-13.3-1.2) 
0.8834 
 
 
0.0106 
 
 
 
 
0.0011 
 
 
 
 
 
0.5934 
 
 
 
 
0.1830 
 
 
 
 
0.0955 
 
 
 
 
 
0.9439 
 
 
0.7876 
 
 
 
 
0.2883 
 
 
 
 
 
0.2365 
 
0.517 
1
 Data is presented in mean (95% CI); adjusted for Age. 
* Test for treatment effect between GTE and placebo groups at time point using ANCOVA (GLM). 
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3 
Test for overall treatment, time, and treatment by time, effects between GTE and placebo   
  groups using mixed methods for repeated measures. 
4 
Test for overall interaction between treatment group and stratified variables using mixed  
  methods for repeated measures. 
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Table 6.  Treatment Effect: by Statin Users and Non-Users 
 
 
 
Measure
 
(mg/dL)
1
 
Statin Users 
GTE (n=91)  Placebo (n=91) 
Non-Users of Statins 
GTE (n=338)  Placebo (n=364) 
 
change 
Mo.0 to 
Mo.6 
change  
Mo.0 to  
Mo.12 
p values change 
Mo.0 to 
Mo.6 
change  
Mo.0 to 
Mo.12 
p values 
 
Inter.
5
 Trt
3
 Time
3
 
Trt* 
Time
3
 
Trt
4
 Time
4
 
Trt* 
Time
4
 
TC 
    GTE 
    Placebo 
    p
2
 
 
-4.0 (-9.3-1.2) 
3.4 (-1.8-8.7) 
0.0510 
 
-0.2 (-5.9-5.5) 
3.7 (-2-9.5) 
0.3444 
0.1000 0.2964 0.3955  
-7.3 (-9.4-5.3) 
-1.3 (-3.2-0.7) 
<.0001
 
 
-5.8 (-7.9-3.7) 
1.0 (-1-3.1) 
<.0001 
<.0001 0.0111 0.6948 0.865 
HDL 
    GTE 
    Placebo 
    p
2
 
 
-0.4 (-2.1-1.4) 
1.0 (-0.7-2.7) 
0.2882 
 
-0.5 (-2.1-1) 
0.1 (-1.5-1.7) 
0.5849 
0.3155 0.4441 0.6302 
 
-1.4 (-2.3-0.6) 
0.5 (-0.4-1.3) 
0.0023
 
 
-0.1 (-1-0.8) 
1.0 (0.1-1.8) 
0.0915 
0.0056 0.0056 0.2216 0.688 
TG 
    GTE 
    Placebo 
    p
2
 
 
7.9 (0.9-14.8) 
-3.9(-10.9-3.1) 
0.0208 
 
10.0 (2.8-17.1) 
-2.8 (-9.9-4.4) 
0.0145 
0.0047 0.5614 0.8735  
0.4 (-2.7-3.4) 
-0.7 (-3.7-2.2) 
0.6080 
 
1.8 (-1.8-5.3) 
-1.4 (-4.9-2) 
0.2101 
0.2435 0.8199 0.4535 0.014 
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1
 Data is presented in mean (95% CI); adjusted for Age and BMI. 
2
 Test for treatment effect between GTE and placebo groups at time point using ANCOVA (GLM). 
3 
Test for overall treatment, time, and treatment by time, effects between GTE and placebo groups (statin users) using mixed methods for repeated 
measures. 
4 
Test for overall treatment, time, and treatment by time, effects between GTE and placebo groups (non statin-users) using mixed methods for repeated 
measures. 
5 
Test for overall interaction between treatment effect and statin use using mixed model for repeated measures. (inter.=interaction) 
 
LDL 
    GTE 
    Placebo 
    p
2
 
 
-5.2 (-9.8-0.7) 
3.3 (-1.3-7.8) 
0.0108 
 
-1.6 (-6.9-3.7) 
4.2 (-1.1-9.5) 
0.1331 
0.0257 0.1637 0.4303  
-6.0 (-7.8-4.2) 
-1.4 (-3.2-0.3) 
0.0004 
 
-5.9 (-7.7-4) 
0.3 (-1.5-2.1) 
<.0001 
<.0001 0.1797 0.2538 0.441 
C:HDLr 
    GTE 
    Placebo 
    p
2
 
 
0.0 (-0.1-0.1) 
0.0 (-0.1-0.1) 
0.6821 
 
0.0 (-0.1-0.2) 
0.1 (-0.1-0.2) 
0.7016 
0.6500 0.3835 0.9465  
-0.1 (-0.1-0) 
0.0 (-0.1-0) 
0.2781 
 
-0.1 (-0.1-0) 
-0.1 (-0.1-0) 
0.2045 
0.1698 0.4945 0.7858 0.913 
NonHDLC 
    GTE 
    Placebo 
    p
2
 
 
-3.7 (-8.6-1.3) 
2.5 (-2.5-7.4) 
0.0868 
 
0.3 (-5.5-6.2) 
3.6 (-2.2-9.5) 
0.4355 
0.1721 0.1533 0.4594  
-5.9 (-7.8-4) 
-1.7 (-3.5-0.1) 
0.0019 
 
-5.7 (-7.7-3.6) 
0.1 (-1.9-2) 
<.0001 
<.0001 0.1533 0.3303 0.964 
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Appendix 1:  Catechin Content of Study Capsules 
 
 
 
 
Catechin Content of Capsules (mean value in mg, by batch) 
  
EGC (mg) 
 
EC (mg) 
 
EGCG (mg) 
 
ECG (mg) 
 
Total (mg) 
 
Batch 1 25 25 198 42 297 
Batch 2 <1 21 211 63 307 
Batch 3 1 24 210 73 323 
Batch 4 1 22 205 68 310 
Batch 5 1.8 21 209 64 309 
Batch 6 64 33.5 237.5 33 384 
Batch 7 56 29 207 28 334 
Batch 8 63 37 204 32 359 
Mean 26.6 26.6 210.2 50.4 327.9 
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CONSENT FORM 
Study Title:  Green tea and reduction of breast cancer risk 
  
You are invited to be in a research study of how green tea extract consumption affects 
levels of biological factors (biomarkers) that may influence breast cancer risk. We ask 
that you read this form and ask any questions you may have before agreeing to be in the 
study. This study is being conducted by Mindy Kurzer, Ph.D., Jian-Min Yuan, M.D, Tim 
Emory, M.D., Carolyn Torkelson, M.D. of the University of Minnesota and Karen 
Swenson, Ph.D of Park Nicollet.   
 
The purpose of this study is to determine the effect of green tea consumption on breast 
cancer biomarkers, such as mammographic density and sex hormone levels, to further 
understand how green tea might reduce the risk for breast cancer.  Although there is 
research that indicates that green tea reduces risk for breast cancer, not much is known 
about how green tea reduces risk. We think that green tea might change the way women 
metabolize estrogen, a sex hormone. We also think that green tea may reduce oxidative 
stress. Both of these physical changes have been shown to reduce breast cancer risk. If 
we can show that green tea changes these factors for the better, it will help us to better 
understand how green tea reduces risk for breast cancer. In addition, we are going to 
evaluate specific genetic variations to find out whether these genetic variations influence 
your physiological responses to the protective effects of green tea on biomarkers of breast 
cancer risk.   
 
The genetic testing done in this study will measure genetic markers that are not related to 
breast cancer risk or risk of any other disease.  We will simply be examining genetic 
variations that may influence your physiological response to green tea consumption. 
Catechol-O-methyltransferase (COMT) is the main enzyme responsible for breakdown 
and excretion of the active compounds in green tea that we think are responsible for the 
cancer-preventive effects. Previous studies have shown that people with the low-activity 
COMT (which is more common) gene benefit more from possible anti-carcinogenic 
properties of green tea than people with the high-activity COMT gene (which is less 
common). We will also test two other genes that help break down these green tea 
compounds: SULT and UGT genes. You will not receive any results or counseling 
regarding the genetic testing.  No genetic markers related to disease risk will be 
evaluated. 
 
Procedures: 
We anticipate that we will screen up to 8,000 women to find the required 800 participants 
and place them into either the treatment or control group according to a process that will 
not be under your control or the study investigators’.  First, we will perform blood tests to 
confirm that you meet the study criteria and to evaluate your genetic variations in the 
COMT gene.  The results of these tests will determine whether or not you can continue 
with the study.  Once we have determined that you are eligible to continue, the process 
used to place participants into groups will be random (like the flip of a coin). Half the 
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participants will be placed in the treatment group and will consume two green tea extract 
capsules twice per day (two in the morning and two in the afternoon) for one year. The 
other half will be placed in the control group and will consume two placebo capsules 
twice per day for one year. Capsule assignments will be made by the University of 
Minnesota Medical Center/Fairview Investigational Drug Services (IDS) Pharmacy.  
Green tea extract and placebo capsules will be identical and will be administered to the 
subjects by a research staff member or nurse at the HNRC blinded to the contents in the 
capsules. Once you are placed into the treatment or control group it will not be possible 
to change groups.  Neither you nor the investigators will know which group you are in.  
 
Please note that even though you may initially qualify for participation, you may not be 
invited to participate in the study after the first blood tests are performed. 
If you agree to be in this study, we would ask you to do the following things:  
1. Go to the Human Nutrition Research Clinic (HNRC) at the Food Science and 
Nutrition Department of the University of Minnesota in Saint Paul, MN 10 times 
during a 12-month time period. All ten clinic visits will involve a blood draw. At 
five clinic visits, urine samples will also be collected.  Clinic visits 3, 4, 6 and 7 
have the option of being completed at Fairview Crosstown, Fairview Jonathan, 
Fairview Oxboro, Fairview Maple Grove and Fairview Farmington.  The visits 
are described in detail below. 
2. At the beginning of the study and at the 6th and 12th month, collect all urine for 24 
hours in jugs that will be provided.   
3. Go to the University of Minnesota Medical Center (UMMC)/Fairview Breast 
Center, Fairview Southdale Breast Center, or Fairview Maple Grove Breast 
Center for your routine annual mammogram at the end of the study. 
4. Allow a portion of the blood drawn at the first clinical blood draw (about 1 
tablespoon) to be used for DNA analysis. DNA will be isolated from your blood 
sample and stored. We will then analyze the gene variations, which will allow us 
to determine if these gene variations influence your response to green tea extract 
consumption.  
5. Keep your body weight stable during the study, and do not participate in any 
weight loss or weight gain studies or programs.   
6. Consume four capsules per day for one year, containing either green tea extract or 
placebo, as decided by the researchers on a full stomach only, two in the morning 
and two in the afternoon. 
7. Refrain from drinking more than one cup of green tea per week while 
participating in the study. 
8. Refrain from drinking more than 7 alcoholic beverages per week while 
participating in the study.  
 
Here is the list of measurements to be made in this study 
 Body weight 
 Height 
 Waist and hip circumferences 
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 Blood pressure, heart rate, respiratory rate and body temperature 
 Completing a Food Frequency Questionniare 
 Completing a Health History  Questionnaire 
 Completing a Menopause-Specific Quality of Life questionnaire 
 Blood collections (a little more than 1- 4 tablespoon(s) depending on the clinic 
visit, 14 times) for evaluation of plasma F2-isoprostanes (marker of oxidative 
stress), insulin like growth factor –1 (IGF-1) and its binding proteins (these 
are biomarkers for breast cancer), reproductive hormones, liver enzymes, 
vitamin D, glucose, insulin, HbA1c (a blood test for determining your blood 
glucose over prolonged periods of time), C-peptide (a factor useful in 
assessing insulin function and secretion), HDL-Cholesterol, LDL-C, Total-C, 
TG (lipid factors), oxidized LDL-C (a risk factor for heart disease), hsCRP, 
IL-1β, IL-6, IL-8, TNF-α (proteins in blood involved in immune system 
regulation), prolactin (a hormone that affects growth of the mammary glands), 
adiponectin (a protein that regulates glucose and lipids metabolism), 
osteocalcin, pyridinolines, osteoprotegerin, CTX and NTX (biomarkers for 
bone metabolism), ghrelin and leptin (hormones involved in appetite and 
weight regulation), catechins (green tea bioactive compounds), HBsAg, anti-
HBc, anti-HCV (markers for hepatitis B and C), assessing DNA repair 
capacity and specific changes in the following genes that are related to 
metabolism of the green tea bioactive compounds: COMT, GSTM1, GSTT1, 
UGT, SULT, IGF-1, IGFBP-3, PIK3CB and HSD3B1  
 Urine collection (two spot urines at the clinic in 10% of the subjects and three 
24-hour complete collections for all subjects) for measurement of creatinine (a 
muscle metabolite), estrogens and catechins   
 Mammogram to evaluate the changes in your breast density from baseline 
visit to the end of the study. Breast density changes measured by the 
mammograms will be calculated by aid of a computer program. 
 
 
Detailed Description of Clinic Visits: 
Clinic visit 1  
This clinic visit will take place at the Human Nutrition Research Clinic (HNRC), Food 
Science and Nutrition, University of Minnesota Saint Paul, MN. Measurements taken at 
this visit (hepatitis B and C virus infection, liver function and COMT gene variations) 
will be used to make the final assessment of eligibility. A trained medical professional 
will weigh you, measure your height, take your blood pressure while you are resting and 
then draw 45mL (about 3 tablespoons) of blood. You will be sent home with a urine 
collection container and instructions should you meet all inclusion criteria and return for 
Visit 2 to be randomized into the study.  If you are found to be ineligible due to not 
fulfilling the criteria for inclusion in the study after this visit, you will be notified within 
one month, released from the study and thanked for your time.  This visit will take 
approximately 30 minutes. 
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Clinic visit 2 
This clinic visit takes place at the HNRC after checking your eligibility at the first clinic 
visit. You should not have had anything to eat or drink other than water for 10 hours prior 
to your clinic visit. A trained medical professional will weigh you, measure your height, 
take your blood pressure while you are resting and will draw 65mL blood (about 4 
tablespoons). After that, your waist and hip circumferences will be measured using a tape 
measure. You will also complete a health survey, a quality of life questionnaire and a 
food frequency questionnaire as part of this visit. At the end of this visit, you will be 
given your first 3 month supply of capsules and a study log for recording pills which you 
have taken. You will also bring the first 24-hour urine collection to the HNRC at this 
visit. This urine was collected the day before and kept refrigerated until delivery to the 
HNRC.  The visit will take approximately 30 minutes . 
 
Clinic visit 3 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 2. A trained medical professional will 
draw 5mL (about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 4  
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 3. A trained medical professional will 
draw 5mL (about one teaspoon) of your blood.  This visit will take approximately 30 
minutes. 
 
Clinic visit 5  
This clinic visit takes place approximately one month after clinic visit 4. A study staff 
member will weigh you and measure your blood pressure, body temperature and heart 
rate while you are resting.  The trained medical professional will draw 5mL of blood 
(about one teaspoon), and you will provide a urine sample. You will be asked to bring 
your empty or partially empty bottles of your capsules and study log to this visit. At the 
end of this visit, you will be given your next 3-month supply of capsules and materials to 
complete your 24 hour urine collection for clinic visit 8 in several months. This visit will 
take approximately 30 minutes.  
 
Clinic visit 6 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 5.  A trained medical professional will 
draw 5mL (about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 7 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
within one month after clinic visit 6. A trained medical professional will draw 5mL 
(about one teaspoon) of blood. This visit will take approximately 30 minutes.   
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Clinic visit 8 
This visit takes place at the HNRC approximately one month after your clinic visit 7. You 
will be asked to not eat or drink anything but water for 10 hours prior to your clinic visit 
and to bring your empty or partially empty bottle of capsules and study log.  A study staff 
member will weigh you and measure your blood pressure, body temperature and heart 
rate while you are resting. A trained medical professional will draw 65mL blood (about 4 
tablespoons). You will also bring your 24-hour urine collection from the previous day. 
This urine should have been collected the day before and kept refrigerated until delivery 
to the HNRC. You will be asked to bring your empty or partially empty bottles of your 
capsules and pill diary. As part of this visit, you will complete a quality of life 
questionnaire, and you will be given your next 3 month supply of capsules. This visit will 
take approximately 30 minutes. 
 
Clinic visit 9 
This visit takes place at the HNRC approximately three months after your clinic visit 8. 
This visit repeats the tests and measurements taken in clinic visit 5. A study staff member 
will weigh you, measure your blood pressure, body temperature and heart rate while you 
are resting. A trained medical professional will draw 5mL of blood (about one teaspoon). 
At this visit, you will also provide a urine sample. You will be asked to bring your empty 
or partially empty bottles of your capsules and study log. At the end of this visit, you will 
be given your last 3 month supply of capsules and materials to complete your 24 hour 
urine collection for clinic visit 10 in several months. This visit will take approximately 30 
minutes.  
 
 
Clinic visit 10 
This is your last clinic visit. This visit will be scheduled at the HNRC approximately 
three months after your clinic visit 9, during month 12 of your participation. You will be 
asked to not eat or drink anything but water for 10 hours prior to this visit and to bring 
your empty or partially empty bottle of capsules, study log and 24-hour urine collection. 
This urine should have been collected the day before and kept refrigerated until delivery 
to the HNRC.  A study staff member will weigh you, measure your blood pressure, body 
temperature and heart rate while you are resting. Your waist and hip circumferences will 
be measured as well. A trained medical professional will draw 65mL of blood (about 4 
tablespoons). You will also complete a quality of life questionnaire and a food frequency 
questionnaire as part of this visit. This visit will take approximately 30 minutes. 
 
Specific procedures to be performed: 
 
Food Frequency Questionnaire  
At clinic visits 2 and 10 you will complete a questionnaire about your eating habits over 
the past year. This survey is given in a web-based format and should take about 60 
minutes.  
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Menopause-Specific Quality of Life Questionnaire 
At clinic visits 2, 8, and 10 you will answer questions regarding your experience of 
certain physical, psychosocial, and sexual symptoms over the previous week. These 
questions are designed to assess your quality of life in association with your menopausal 
experience. The required time to complete this questionnaire will be less than 15 minutes. 
 
Collection of 24-hour urine samples 
The day before clinic visits 2, 8 and 10, you will collect all urine for a 24-hour period in 
jugs that we provide to you. You will keep them refrigerated and bring them to the clinic 
at the time of your visit. 
 
Mammogram 
As part of your routine medical checkup, you will undergo one mammogram within one 
week of finishing the study.  Also, you might need to wait for your next annual 
mammogram until the Green Tea Study is over, which could be up to 15-16 months from 
your initial mammogram. 
 
Risks of Being in the Study: 
Participating in this study has the following risks: 
 
First, liver toxicity has been seen in a few subjects who used green tea extract as a weight 
reduction aid. The risk of toxicity from taking manufactured green tea extracts has been 
estimated to be about 1 case out of 83,812 treatments, although no toxicity has been 
reported in any clinical trials performed to date. To be cautious, we will measure liver 
enzymes 9 times throughout our study for possible toxicity and tolerance at each visit at 
the HNRC or a Fairview clinic. If your liver enzymes are elevated, you will be informed 
and released from the study. 
 
Second, as with any dietary supplement or pharmaceutical, there is a slight risk of 
stomach upset, nausea, vomiting, and diarrhea.  To prevent any of these digestive 
problems, we advise that you take the study supplement on a full stomach, after breakfast 
and after dinner.  There is also a slight risk of headache from consuming the study 
supplement.  If discomfort persists, you may contact the study coordinators. 
 
You may experience discomfort from hunger and feel inconvenienced by having stop 
eating 10 hours before the blood draws at visits 2, 8 and 10 of the study.   
 
Also, there is a small risk of infection and bruising at the needle puncture site when blood 
is taken. The risk is minimal as all needles and equipment are sterilized and the 
procedures are performed by trained phlebotomists: registered nurses and certified 
medical assistants at the HNRC or a Fairview clinic. You may also feel some pain, 
dizziness, or feel faint lasting a few seconds upon insertion of the needle used to draw the 
blood. 
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Lastly, screening mammography is the best way to detect early breast cancers.  You are 
currently getting your mammograms approximately every 12 months.  If you participate 
in this study, your mammogram may be delayed by at most 3-4 months.  Some experts 
(U.S. Preventive Services Task Force, 2009) have suggested that this type of delay has 
little effect on the benefits of mammography.  If you wish to have your regular 
mammogram on a yearly basis, we will ask you to have a second limited view research 
mammogram after you have been on the study for 1 year.  The additional limited view 
mammogram would be at no cost to you. 
   
Benefits of Being in the Study: 
There may be no direct reduction of breast cancer risk as a result of participation in this 
study. Additionally, upon your request we can send the first liver function test results 
conducted at your screening visit to you or your primary care physician. 
 
Costs:   
No charges will be made for the Human Nutrition Research Clinic (HNRC) any Fairview 
clinic visits while you are a participant in this study. 
 
Compensation  
You will also receive financial compensation of up to $450 for study participation:  $20 
for completing the first clinic visit, $70 for the next four clinic visits (clinic visits 2, 3, 4 
and 5), $100 for the next three clinic visits (6, 7, 8), $60 for clinic visit 9, and $100 for 
completing the last clinic visit (clinic visit 10). Finally, upon completion of all clinical 
research endpoints (visits, questionnaires and mammogram), you will receive another 
$100 at the end of the study.   
 
Participants found ineligible after completing the first clinic visit will receive $20.00.  
Participants who become ineligible during the study will receive pro-rated compensation. 
 
Care in the case of injury 
In the event that this research results in an injury, treatment will be available, including 
first aid, emergency treatment, and follow-up care as needed. Care for such injuries will 
be billed in the appropriate manner, to you or your insurance company. If you think that 
you have suffered a research-related injury, let the principal investigator or a study 
coordinator know right away Dr. Mindy Kurzer: (612-624-9789) or study coordinators: 
(612-624-3412). 
 
Your participation in the study may be terminated by the investigator without 
regard to your consent in the following circumstances: 
1. Failure to come to clinic visits after one reschedule 
2. Circumstances change so that you are no longer eligible  
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Confidentiality: 
The information provided by you and the information taken from the measurements of 
your body will be held strictly confidential and used for the purposes of research only. 
The HNRC, whose staff has completed the federally required training with regard to 
confidentiality of health information in research, will maintain medical records with your 
name on them for the purposes of scheduling and billing procedures only. Any/all 
medical information gathered, test results, lab samples will NOT have your name on 
them. Instead, they will be labeled with a study ID number only. 
 
Laboratory results and other test results will not be included in the medical record. Your 
name will be associated with your study ID number on one list, to be kept in a locked file 
cabinet.  Your study ID number will appear on all other study records.  Representatives 
of the University of Minnesota or the National Institutes of Health may be given access to 
your records to assure that the study is conducted properly. 
 
All your study records will be kept private, in locked storage according to HIPAA 
standards. None of your information will ever be given to anyone, and your name will 
never be associated with your records on paper or on computer.  In any sort of report we 
might publish, we will not include any information that will make it possible to identify 
you as a subject of this study.  
 
With regard to your blood and urine samples:  
 We will send samples of your blood with only a code number on it to the 
University of Southern California (USC) to analyze it for biomarkers of breast 
cancer called IGF-1, binding proteins for IGF-1, as well as reproductive 
hormones. USC will be paid to do these tests .We will NOT tell USC researchers 
your name or give them any identifying information about you. Any excess blood 
will be destroyed when researchers have completed these tests.  
 
 We will send samples of your blood and urine with a code number on it to 
Rutgers University to analyze it for plasma and urine catechin levels. Rutgers 
University will be paid to do these tests. We will NOT tell Rutgers University 
researchers your name or give them any identifying information about you. Any 
excess blood and urine will be destroyed when researchers have completed with 
these tests.  
 
 We will store any remaining blood and urine in a freezer in the Food Science and 
Nutrition Building at the University of Minnesota (St. Paul campus). The vials 
will have your study ID on them and the date on which the blood was drawn. 
Your name will NOT be stored with your blood. We will store these vials for up 
to 5 years after the entire study is over. The freezer in which they are stored is 
kept behind a locked door. The only people who have access to this freezer are 
paid research staff members who have completed the federally required training 
with regard to confidentiality of health information in research. The purpose for 
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storing these samples is to enable us to conduct additional tests regarding green 
tea health effects. The principal investigator will maintain ownership of these 
samples while they are stored. Samples will be destroyed within five years after 
the completion of the study. You will not receive any results from future tests 
conducted with these stored samples.  
 
 USC and Rutgers University labs do NOT have access to your name. There is one 
confidential list and file that links your ID to your name. These files will be kept 
in the locked file cabinet as described above. The only people who will have 
access to this list are the principal investigator (Dr. Kurzer) and her research staff, 
who have completed the federally required training with regard to confidentiality 
of health information in research.   
 
Protected Health Information (PHI) 
Your PHI created or received for the purposes of this study is protected under the federal 
regulation known as the Health Insurance Portability and Accountability Act of 1996 
(HIPAA).  Refer to the accompanying HIPAA authorization for details concerning the 
use of this information.  
 
A new federal law (2009), called the Genetic Information Nondiscrimination Act (GINA) 
generally makes it illegal for health insurance companies, group health plans, and 
employers of 15 or more persons to discriminate against you based on your genetic 
information. Health insurance companies and group health plans may not request your 
genetic information that we get from this research. This means that they may not use your 
genetic information when making decisions regarding insurability. Be aware that this 
new federal law will not protect you against genetic discrimination by companies that 
sell life insurance, disability insurance, or long-term care insurance. 
 
Voluntary Nature of the Study: 
Your decision whether or not to participate will not affect your current or future relations 
with the University. If you decide to participate, you may withdraw at any time without 
affecting those relationships.  In addition, you may request your blood and urine samples 
to be destroyed following your withdrawal from the study. The procedure to withdraw is 
to call Mindy Kurzer, Ph.D. at (612) 624-9789 or the study coordinators at (612) 624-
3412 and inform them that you wish to withdraw.   
 
New Information: 
If during the course of this research study, there are significant new findings discovered 
that might influence your willingness to continue, the researchers will inform you of 
those developments. 
 
Contacts and Questions: 
The primary researcher conducting this study is Mindy Kurzer, Ph.D.  If you have 
questions, you may contact her at the Department of Food Science and Nutrition, 
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University of Minnesota, 1334 Eckles Ave., St. Paul, MN 55108. Phone: (612) 624-9789; 
email: mkurzer@umn.edu. You may also contact the study coordinators in the 
Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave., 
St. Paul, MN 55108. Phone: (612) 624-3412; email: greentea@umn.edu. 
  
If you have any questions or concerns regarding the study and would like to talk to 
someone other than the researcher(s), you are encouraged to contact the Fairview 
Research Helpline at telephone number (612)672-7692 or toll-free at (866) 508-6961. 
You may also contact this office in writing or in person at University of Minnesota 
Medical Center/Fairview Riverside Campus, 2200 Riverside Avenue, Minneapolis, MN 
55454. 
 
Statement of Consent: 
I have read the above information. I have asked questions and have received answers. I 
consent to participate in the study.  
 
________________________________________________________________________    
Signature of Participant                                                                                   Date 
 
________________________________________________________________________ 
Name of Participant (printed) 
 
________________________________________________________________________ 
Street Address          City       State      Zip code 
 
________________________________________________________________________    
Signature of Person Obtaining Consent                Date 
 
You will be given a copy of this form for your records. 
 
 
 
